

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Risk Assessment for Acute Kidney Injury and Death among New COVID-19 Positive Adult Patients without Chronic Kidney Disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053635
Article Type:	Original research
Date Submitted by the Author:	20-May-2021
Complete List of Authors:	Li, Daniel; Harvard University T H Chan School of Public Health; Johns Hopkins School of Medicine Ren, Hui; Harvard Medical School, Department of Radiology Varelmann, Dirk J.; Brigham and Women's Hospital, Department of Anesthesiology Sarin, Pankaj; Brigham and Women's Hospital, Department of Anesthesiology Xu, Pengcheng; Harvard Medical School, Department of Radiology Wu, Dufan; Harvard Medical School, Department of Radiology Li, Quanzheng; Harvard Medical School, Department of Radiology Lin, Xihong; Harvard University T H Chan School of Public Health, Department of Biostatistics; Harvard University, Department of Statistics
Keywords:	COVID-19, EPIDEMIOLOGY, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 1 **Title Page**  
4

5 2  
6 3 **Risk Assessment for Acute Kidney Injury and Death among New COVID-19**  
7 4 **Positive Adult Patients without Chronic Kidney Disease**  
8 5

9 6 *Short Title:* AKI and Death among COVID-19 Patients without CKD  
10 7

11 8 Daniel Li, MD, MA,<sup>1,2\*</sup> Hui Ren, MD, PhD, MPH<sup>3\*</sup> Dirk J. Varelmann, MD,<sup>4</sup> Pankaj Sarin,  
12 9 MD,<sup>4</sup> Pengcheng Xu, BS,<sup>3</sup> Dufan Wu, PhD,<sup>3</sup> Quanzheng Li, PhD,<sup>3\*\*</sup> Xihong Lin,  
13 10 PhD<sup>1,5,6\*\*</sup>  
14  
15

16  
17 11 \*Contributed equally, co-first authorship  
18

19 12 <sup>1</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston MA.  
20

21 13 <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore MD.  
22

23 14 <sup>3</sup>Department of Radiology, Massachusetts General Hospital and Harvard Medical  
24 15 School, Boston MA.

25 16 <sup>4</sup>Department of Anesthesiology, Brigham and Women's Hospital, Boston MA.  
26

27 17 <sup>5</sup>Department of Statistics, Harvard University, Cambridge MA.  
28

29 18 <sup>6</sup>Broad Institute of MIT and Harvard, Cambridge, MA.  
30  
31

32 20 **\*\*Correspondence:** Xihong Lin, Quanzheng Li  
33

34 21 Department of Biostatistics  
35

36 22 655 Huntington Ave  
37

38 23 Building II, Room 419  
39

40 24 Boston, MA 02115  
41

42 25 Telephone: 617 432 2914  
43

44 26 Fax: 617 432 5619  
45

46 27 **Email:** [xlin@hsph.harvard.edu](mailto:xlin@hsph.harvard.edu), [li.quanzheng@mgh.harvard.edu](mailto:li.quanzheng@mgh.harvard.edu)  
47

48 29 Abstract 277 words; Main Text 3,138 words; References 32; Tables 4; Figures 1;  
49 30 Appendix Tables 5  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Abstract

2 **Objective:** To develop simple but clinically informative risk stratification tools using a  
3 few top demographic factors and biomarkers at COVID-19 diagnosis to predict acute  
4 kidney injury (AKI) and death.

5 **Design:** Retrospective cohort analysis, follow-up from February 1 through May 28,  
6 2020.

7 **Setting:** 3 teaching hospitals, 2 urban and 1 community-based in the Boston area.

8 **Participants:** Eligible patients were at least 18 years old, tested COVID-19 positive  
9 from February 1 through May 28, 2020, and had at least two serum creatinine  
10 measurements within 30 days of a new COVID-19 diagnosis. Exclusion criteria were  
11 having CKD or having a previous AKI within 3 months of a new COVID-19 diagnosis.

12 **Main Outcomes and Measures:** Time from new COVID-19 diagnosis until AKI event,  
13 time until death event.

14 **Results:** Among 3,716 patients, there were 1,855 (49.9%) males and the average age  
15 was 58.6 years (SD 19.2 years). Age, sex, white blood cell, hemoglobin, platelet, C-  
16 reactive protein, and D-dimer levels were most strongly associated with AKI and/or  
17 death. We created risk scores using these variables predicting AKI within 3 days and  
18 death within 30 days of a new COVID-19 diagnosis. Area under the curve (AUC) for  
19 predicting AKI within 3 days was 0.785 (95% CI, 0.758 to 0.813) and AUC for death  
20 within 30 days was 0.861 (95% CI, 0.843 to 0.878). Hemoglobin was the most predictive  
21 component for AKI, and age the most predictive for death. Predictive accuracies using  
22 all study variables were similar to using the simplified scores.

1 **Conclusion:** Simple risk scores using age, sex, a complete blood cell count, C-reactive  
2 protein, and D-dimer were highly predictive of AKI and death and can help simplify and  
3 better inform clinical decision making.

4 **Key words:** COVID-19; kidney injury; risk prediction

### 6 **Strengths and limitations of this study**

- 7 • Various associations between patient variables and COVID-19 acute kidney  
8 injury AKI and death have been reported, but it is unclear which variables are  
9 most predictive and important to focus on.
- 10 • We developed risk scores for predicting AKI and death among new COVID-19  
11 positive patients.
- 12 • Readily obtainable demographic, vital sign, and laboratory values were  
13 considered evaluated.
- 14 • Findings are limited to patients without chronic kidney disease.

## 1 Introduction

2 Although respiratory failure and diffuse inflammatory lung tissue damage are key  
3 features of coronavirus disease 2019 (COVID-19), involvement of other organs such as  
4 the kidneys has been well documented. Pathologic autopsy examinations of COVID-19  
5 kidneys have shown clusters of coronavirus-like particles in the tubular epithelium and  
6 podocytes, upregulation of the severe acute respiratory syndrome coronavirus 2  
7 (SARS-CoV-2) receptor angiotensin-converting enzyme 2 and positive immunostaining  
8 with SARS-CoV-2 nucleoprotein antibodies.<sup>1,2</sup> Hemodynamic instability, systemic  
9 hypoxia, abnormal coagulation, and inflammation from severe COVID-19 can also  
10 directly contribute to acute kidney injury (AKI) and induce acute tubular necrosis.<sup>3</sup>

11 Various epidemiologic studies from China, Europe, and the United States have  
12 investigated AKI outcomes among COVID-19 patients. Early studies in China have  
13 reported AKI incidences ranging from 0.5-15% among hospitalized and outpatient  
14 COVID-19 patients.<sup>4,5</sup> One United Kingdom study found hospitalized COVID-19 patients  
15 with AKI had a 3-fold higher odds of death than those without AKI.<sup>6</sup> Large US population  
16 studies of hospitalized COVID-19 patients, primarily in the New York City metropolitan  
17 area, have reported AKI incidences ranging from 27-57%, with in-hospital mortality rates  
18 ranging from 35-71% among AKI COVID-19 patients.<sup>7-10</sup> Some of these studies have  
19 also explored variable associations with COVID-19 AKI, but none of these studies have  
20 investigated which subset of these variables are most predictive of AKI or built risk  
21 predictions models using demographic variables and biomarkers.

22 Risk prediction tools have been investigated for COVID-19 deaths. A small  
23 number of a priori determined biomarkers were investigated for their associations with

1 the risk of COVID-19 death.<sup>11</sup> However, a more data driven approach would compare  
2 the predictive accuracies of these biomarkers to other biomarkers and variables such as  
3 demographic factors and vital signs and build a more powerful risk prediction model  
4 using a comprehensive set of biomarkers, demographic variables, and vital signs.  
5 Different risk factors should also be weighted differently, and understanding the relative  
6 importance of different variables in predicting poor outcomes will allow for more  
7 accurate holistic patient evaluations.

8 In this study we developed and evaluated new risk assessment tools that can be  
9 easily implemented at the bedside or during chart reviews to predict AKI and death after  
10 a positive COVID-19 test. Our contributions include (1) identifying the top biomarkers  
11 and demographic variables that predict AKI events among COVID-19 patients, (2)  
12 investigating a greater number of potential biomarkers and risk factors in predicting  
13 death, (3) developing clinical risk assessment tools for both AKI and death using a small  
14 number of predictors, and (4) validating that these tools are nearly as predictive as  
15 using all available study variables. By understanding which subset of risk factors are  
16 most important to focus on, medical providers can more efficiently work up and risk  
17 stratify their newly diagnosed COVID-19 patients.

## 19 **Methods**

### 20 *Study Population*

21 The Mass General Brigham (MGB) Health system serves a large diverse patient  
22 population around Boston and Eastern Massachusetts. Electronic health records from



1 three major hospitals in this system (Massachusetts General Hospital in Boston,  
2 Brigham and Women's Hospital in Boston, and Newton-Wellesley Hospital in Newton)  
3 were used. The Mass General Brigham Institutional Review Board approved this study,  
4 and the approval number was 2020P001661.

5 We included all patients that 1) were at least 18 years old, 2) tested COVID-19  
6 positive at one of the three hospitals above between February 1, 2020 through May 28,  
7 2020, and 3) had at least 2 serum creatinine tests within 30 days of their SARS-Cov-2  
8 PCR test. We excluded patients that 1) met the criteria of acute kidney injury within 3  
9 months before their SARS-CoV-2 test and 2) had chronic kidney disease (CKD)  
10 identified as a preexisting condition from International Classification of Disease (ICD-9  
11 and ICD-10) codes (see below).

### 12 13 *Data Collection*

14 Information in electronic health records (EHR) of patients who met the inclusion  
15 criteria were extracted from the enterprise data warehouse and included demographic,  
16 comorbidities, clinical, laboratory, and outcome data (death). Demographic and  
17 laboratory data information closest to the time of first SARS-Cov-2 PCR test were kept  
18 (except for serum creatinine, multiple values were kept). Serum creatinine laboratory  
19 test results and timestamps within 3 months before and 30 days after the SARS-Cov-2  
20 polymerase chain reaction test were extracted. We categorized ethnic groups other than  
21 White, Black, Hispanic, and Asian into a single subgroup. All documented comorbidity  
22 related medical history in MGB healthcare system enterprise data warehouse before the

1 first time of SARS-Cov-2 test were extracted. Preexisting conditions, including  
2 hypertension, diabetes, cardiovascular disease, and heart failure, were classified using  
3 their ICD-9 or ICD-10 codes.

### 4 *Definitions of Outcomes*

5  
6 Per the Kidney Disease Improving Global Outcomes (KDIGO) criteria, AKI was  
7 defined as a change in serum creatinine (SCr) of 0.3 mg/dl over a 48-hour period, a  
8 50% increase in baseline creatinine in 7 days, or urine value <0.5 ml/kg/hour for 6  
9 hours.<sup>12</sup> Due to difficulties obtaining accurate urine volumes from electronic health  
10 record data, we only use serum creatinine to define AKI events. If patients had more  
11 than 2 SCr tests in their EHR, we used all available SCr tests to define the earliest time.  
12 Death times were directly extracted from the data warehouse.

### 13 14 *Statistical Analyses*

15 Continuous variables were transformed into categorical variables to improve  
16 interpretability of results and account for nonlinear associations. Counts and  
17 percentages were presented, and two proportion z-tests were used to compare the  
18 proportion of deaths among AKI and non-AKI patients. For AKI survival analyses,  
19 observations without AKI were censored after 30 days, at the time of death, or at  
20 5/28/2020, whichever came first. For death survival analyses, observations without  
21 death were censored at 5/28/2020. Multiple multivariable Cox proportional hazards  
22 models included age, sex, race, diabetes, cardiovascular disease, hypertension, heart

1 failure, body mass index (BMI), temperature, heart rate, systolic blood pressure, white  
2 blood cell count (WBC), hemoglobin, platelets, C-reactive protein (CRP), ferritin, D-and  
3 dimer. Given the missing data with respiratory rate interleukin-6 (IL-6) values, we  
4 performed exploratory multiple imputation Cox regression analyses. Additional details  
5 are in the sensitivity analysis section.

6 We next built a simplified Cox model for clinical use by using a stepwise variable  
7 selection procedure for Cox models alternating between “forward” and “backwards”  
8 steps to identify the first 5 variables to be included.<sup>13</sup> Simplified Cox models were fit  
9 using only the selected 5 variables and Harrell’s C-Statistics were obtained (survival  
10 outcome). Model coefficient (linear prediction) accuracy was evaluated. We evaluated  
11 area under receive operating characteristic (ROC) curves (AUC) for predicting AKI  
12 within 3 days and death within 30 days of a new COVID-19 diagnosis (binary outcome).  
13 Net reclassification improvement (NRI) of adding all remaining covariates was also  
14 calculated.

15 Risk scores were obtained by rounding simplified model coefficients for easier  
16 clinical risk assessment use. For suggested risk score cutoffs, Kaplan-Meier event  
17 curves were plotted, log rank tests were performed, and sensitivities, specificities,  
18 positive and negative likelihood ratios were calculated. Approximate pre-test to post-test  
19 probability changes from likelihood ratios were calculated using the linear approximation  
20 proposed by McGee.<sup>14</sup> Cutoffs for low risk were chosen so that the negative likelihood  
21 ratio would be  $\approx 0.20$  with a pre- to post-test probability decrease of  $\approx 30\%$ , while cutoffs  
22 for high risk were chosen so that the positive likelihood ratio would be  $\approx 5.0$  with a pre- to  
23 post-test probability increase of  $\approx 30\%$  and that at least 15% of patients (560) would be

1 identified as high risk.<sup>14</sup>We ran 1,000 internal cross validation iterations in which 70% of  
2 data were randomly assigned to training, the other 30% to testing. For each iteration,  
3 simplified Cox models were fit to the training data, coefficients were rounded to obtain  
4 risk scores, and AUC's were calculated using the predicted testing data risk scores.

5 We performed two sensitivity analyses. First, the multivariable cause-specific and  
6 subdistribution hazard to documented AKI events within 30 days accounting for the  
7 competing risk of death was modeled.<sup>15</sup> Second, we performed a multiple imputation  
8 analysis by creating 10 imputation datasets with imputed values for missing respiratory  
9 rate and IL-6 and then calculating pooled multivariable Cox hazard ratios.<sup>16</sup> All analyses  
10 were performed with R version 4.0.4 and all code for analyses are available online (to  
11 be posted during revisions).

## 13 Results

### 14 *Demographic and Clinical Characteristics*

15 There were 3,716 eligible adult COVID-19 positive patients without CKD, of  
16 which 1,855 (49.9%) were male. The average age was 58.6 years (SD 19.2 years).  
17 There were 696 patients that developed AKI (18.7%) and 249 (35.8%) were within three  
18 days of a new COVID-19 diagnosis. There were 347 deaths (9.3%) and 322 (92.8%)  
19 were within thirty days of a new COVID-19 diagnosis. Among the AKI group there were  
20 192 deaths (27.6%), and among the non-AKI group there were 155 deaths (5.1%,  
21  $p<0.001$ ). Patient demographics, preexisting conditions, vital signs, and laboratory  
22 values stratified by patients with AKI and patients that died are displayed in **Table 1**.

1 Patients with AKI and patients that died were more likely to be older, male, have  
2 multiple comorbidities, and have on admission higher temperatures, lower systolic blood  
3 pressures, higher respiratory rates, elevated white blood cell counts, lower hemoglobin  
4 and platelets, and elevated CRP, ferritin, D-dimer, and IL-6 levels.

### 6 *Fully Adjusted Multivariable Regression*

7 Multivariable Cox regression was performed to identify risk factors associated  
8 with time to AKI and death. **Table 2** displays pooled multivariable adjusted hazard  
9 ratios. Adjusting for all other variables, older age, increased medical conditions,  
10 increased temperature, decreased systolic blood pressure, increased white blood cells,  
11 decreased platelets, and increased CRP and D-Dimer were associated with increased  
12 hazards for both AKI and death. Elevated BMI, decreased hemoglobin, and increased  
13 ferritin were associated with increased hazards for AKI but not death. Black and Asian  
14 race were associated with decreased hazards and increased heart rate was associated  
15 with increased hazards for death but not AKI.

### 17 *Top Risk Factor/Biomarker Selection*

18 The top five variables selected for being most associated with AKI events were  
19 hemoglobin, D-dimer, CRP, WBC, and male sex. The top five variables most associated  
20 with death were age, CRP, platelets, WBC, and D-Dimer. **Table S1** shows model  
21 coefficients and Harrell's C-statistic (survival concordance) from the simplified model  
22 using just these selected variables. **Table S2** shows similar results for the fully adjusted

1 model. The simplified AKI Cox model had a survival C-statistic of 0.785 (95% CI, 0.769  
2 to 0.800), while the fully adjusted AKI Cox model had a C-statistic of 0.813 (95% CI,  
3 0.798 to 0.827). The simplified death Cox model had a survival C-statistic of 0.857 (95%  
4 CI, 0.841 to 0.874), while the fully adjusted death Cox model had a C-statistic of 0.878  
5 (95% CI, 0.863 to 0.892).

6 Cox model coefficients were used to predict AKI events within 3 days and death  
7 within 30 days of a new COVID-19 diagnosis (binary outcomes). **Table S1** and **Table**  
8 **S2** also displays AUC's for the simplified and fully adjusted coefficients respectively. For  
9 AKI in 3 days, using the simplified coefficients had an AUC of 0.787 (95% CI, 0.759 to  
10 0.814), using the fully adjusted coefficients had an AUC of 0.820 (95% CI, 0.794 to  
11 0.845), and the NRI was 0.041 (95% CI, 0.003 to 0.082). For death in 30 days, using  
12 the simplified coefficients had an AUC of 0.872 (95% CI, 0.854 to 0.890), the fully  
13 adjusted coefficients had an AUC of 0.893 (95% CI, 0.878 to 0.909), and the NRI was  
14 0.010 (95% CI, -0.007 to 0.029).

### 16 *Risk Score*

17 Model coefficients were rounded to obtain risk score component values for easier  
18 clinical use. **Table 3** shows the risk score and internal validation results. For AKI in 3  
19 days, the risk score had an AUC 0.785 (95% CI, 0.758, 0.813) and a cross validation  
20 AUC of 0.776 (95% CI, 0.732, 0.816). For death in 30 days, the risk score had an AUC  
21 of 0.861 (95% CI, 0.843 to 0.878) and a cross validation AUC of 0.860 (95% CI, 0.831,  
22 0.886). **Figure 1A** plots ROC curves for using fully adjusted coefficients (from **Table S2**)

1 versus using risk scores (from **Table 3**) in predicting AKI in 3 days and death in 30  
2 days.

3 Suggested risk stratification cutoffs were obtained. **Table S3** presents sensitivity,  
4 specificity, and positive and negative likelihood ratios for all possible risk score cutoffs.  
5 **Table 4** shows suggested risk stratification cutoffs and stratified observed and  
6 estimated event rates. Higher risk scores had higher observed and estimated AKI and  
7 death rates. **Figure 1B** plots Kaplan Meier event curves of AKI and death events by  
8 simplified risk score categories. Event rates different by risk category for AKI ( $p < 0.001$ )  
9 and death ( $p < 0.001$ ).

### 11 *Sensitivity Analysis*

12 We performed a competing risk regression analysis for AKI and death within 30  
13 days. **Table S4** displays the multivariable cause-specific and subdistribution hazard  
14 ratios for AKI events. Cause-specific and subdistribution hazard ratio estimates and  
15 confidence intervals were nearly identical. We also performed a multiple imputation  
16 analysis by imputing missing values for respiratory rate and IL-6 to evaluate their  
17 associations. **Table S5** shows that results were similar to non-imputation results, and  
18 increased respiratory rate and IL-6 were associated with increased hazards of AKI and  
19 death.

### 21 **Discussion**

1 In this retrospective study of over 3,700 adult patients without chronic kidney  
2 disease diagnosed with COVID-19 through May 2020 in the Boston area, we identified  
3 risk factors and biomarkers associated with AKI and death, and we developed and  
4 internally validated risk scores for predicting AKI and death. We found about one in five  
5 patients developed AKI and one in ten patients died. Increased age, male sex,  
6 increased white blood cells, C-reactive protein and D-Dimer and decreased hemoglobin  
7 and platelet levels were associated with AKI within 3 days and/or death within 30 days  
8 of a new COVID-19 diagnosis. A risk score using just these variables had similar  
9 internal accuracy as using all study variables. These results can assist in risk  
10 stratification of COVID-19 patients without CKD.

11 Many studies have found markedly increased COVID-19 fatality rates among  
12 older people. Studies from China, Spain, and Italy, and a meta-analysis of studies from  
13 34 different geographical locations have all found increased case or infection fatality  
14 rates among people >60 and >65 years old compared to younger populations.<sup>17–20</sup> We  
15 similarly observed older age had some of the strongest associations with death. Earlier  
16 studies have found various physiologic changes among elderly patients that may  
17 contribute to this age-related risk, such as decreased small airway clearance,  
18 decreased number of cilia and ciliated cells, and decreased upper airway size.<sup>21–23</sup>

19 Other studies have also reported worse COVID-19 outcomes among men. A  
20 study of over 3,300 patients in Montefiore Medical Center found male sex was  
21 associated with AKI in both COVID-19 positive and negative patients.<sup>8</sup> This study also  
22 provided a more complete discussion of other animal studies and meta-analyses to date  
23 that that have found associations between male sex and AKI in general. Studies of



1 COVID-19 outcomes from March 2020 in Italy and the US also reported increased  
2 hospitalization and intensive care unit admission rates among male patients.<sup>24,25</sup> We  
3 similarly observed that AKI patients (60.3%) and patients that died (58.2%) were more  
4 likely to be male (overall 49.9%). However, after adjusting for other demographics,  
5 medical conditions, vital signs, and laboratory values, we found male sex was  
6 associated with AKI but not death.

7       Among laboratory values, C-reactive protein, hemoglobin, white blood cells, D-  
8 Dimer, and platelets were significantly associated with AKI and death and were included  
9 in risk scores. Although there has been debate about a standard definition for COVID-  
10 19 cytokine storm syndrome, patients with C-reactive protein may have excessive  
11 immune activation, with C-reactive protein being produced by hepatocytes in response  
12 to IL-6 or ferritin.<sup>26</sup> Decreased hemoglobin may be reflective of kidney disease with  
13 decreased erythropoietin production or directly lead to decreased oxygenation of the  
14 kidneys. A study from Korea also found a higher risk of AKI in critically ill patients with a  
15 hemoglobin <10.5 g/dL.<sup>27</sup> Elevated white blood cell counts may suggest sepsis and be  
16 associated with life-threatening organ dysfunction.<sup>28</sup> Elevated D-Dimer levels may be  
17 indicative of a pro-thrombotic state, and a retrospective study from China found that D-  
18 Dimer >2000 ng/mL was associated with increased mortality.<sup>29</sup> However D-dimer levels  
19 have also been reported to be elevated at baseline in CKD patients,<sup>30</sup> so it is possible  
20 elevated D-Dimer may only be prognostic in non-CKD patients. Low platelets may also  
21 indicate a systemic coagulopathic process that places patients at an increased risk for  
22 death.<sup>28</sup>

1           The biomarker IL-6 was found to be a significant risk factor in regression  
2 analyses. However, a substantial proportion of patients in our study were missing IL-6  
3 values (78.3%), so IL-6 was not considered for risk score development. Previous  
4 studies have found IL-6 cutoffs of 80 and 86 IU/mL to have prognostic value for  
5 predicting respiratory failure and death respectively.<sup>31,32</sup>

6           We proposed risk scores for identifying AKI within 3 days and death within 30  
7 days of a new COVID-19 diagnosis along with suggested cutoffs. Although risk scores  
8 still need to be externally validated, being able to identify a few key biomarkers that are  
9 widely accessible can help focus chart reviews of new COVID-19 positive patients.  
10 Varying score weights further highlight biomarkers to focus on, such as hemoglobin and  
11 male sex for AKI, age and platelets for death, and WBC, CRP, and D-Dimer for both.  
12 Larger scores directly correlate with worse outcomes and can help shape physician  
13 gestalt.

14           We explored death being a competing risk for AKI events as patients with death  
15 will not have any more creatinine measurements. Although an AKI does not exclude the  
16 possibility of death, competing risk analyses can still be performed investigating which  
17 event type occurs first.<sup>15</sup> The cause-specific hazards ratios (Cox hazard ratios) describe  
18 the rate of AKI events among those still alive and with no previous AKI events, while the  
19 subdistribution hazard ratios describes the overall rate of AKI events occurring before  
20 death. In our study both cause-specific and subdistribution hazard ratios were similar.  
21 Competing risk analyses were not performed for death events as having an AKI does  
22 not exclude death.

1            Limitations to our study include the following. All results are associational and no  
2            causal effects should be interpreted. Vital and signs and laboratory values were those  
3            closest to COVID-19 diagnosis, and time-varying covariates were not incorporated into  
4            analyses. As the study was retrospective, selection bias cannot be excluded, and only  
5            events within the MGB system were recorded. Our identified risk factors and risk scores  
6            are most applicable during a patient's initial COVID-19 positive test. Patients in the  
7            Boston area may not be reflective of those in other healthcare systems, and the study  
8            population included only COVID-19 positive patients without CKD. Future work may  
9            further stratify AKI events by stage, investigate outpatient, hospitalized, and critically ill  
10           patients separately, focus on CKD patients, and validate results on a separate cohort.

11           We investigated AKI and death outcomes among adult COVID-19 patients  
12           without CKD in the Boston area. We identified risk factors and developed and evaluated  
13           risk assessment tools for identifying COVID-19 patients developing AKI and death.  
14           Hemoglobin, D-Dimer, CRP, WBC, and male sex were the strongest predictive  
15           biomarkers for AKI. Age, CRP, platelets, WBC, and D-Dimer were most predictive for  
16           death. Our study significantly contributes to epidemiological knowledge of COVID-19  
17           outcomes and introduces simple tools to assist with rapid risk assessment.

18

## 19 **Acknowledgements**

20 **Contributors:** None

21 **Funding statement:** This work was supported by the National Institutes of Health grant  
22 number T32-GM135117 (DL).

23 **Competing interests:** The authors declare no relevant competing interests.

24 **Authors' contributions:** DL and HR drafted the manuscript. HR, PX, DW obtained the  
25 data. DL performed the analyses. DL, HR, DJV, PS, QL, and XL contributed to the

1 design of the study. All authors were involved with interpretation of the data and critical  
2 revision and final approval of the article.

3 **Availability of data and materials:** Patient data is not available, but requests for  
4 surrogate data may be made to the corresponding authors. However, code for all  
5 analyses will be available at <https://github.com/lin-lab>.

6 **Patient and public involvement:** Patients were not involved in planning of this project.

7 **Research ethics approval human subjects:** The Mass General Brigham Institutional  
8 Review Board approved this study, and the approval number was 2020P001661. Only  
9 deidentified patient electronic health record data were used.

10

For peer review only

## References

1. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. 2020;98(1):219-227. doi:10.1016/j.kint.2020.04.003
2. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. *JASN*. 2020;31(8):1683-1687. doi:10.1681/ASN.2020040432
3. Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol*. Published online October 15, 2020. doi:10.1038/s41581-020-00356-5
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
5. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
6. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. Remuzzi G, ed. *PLoS Med*. 2020;17(10):e1003406. doi:10.1371/journal.pmed.1003406
7. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney International*. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
8. Fisher M, Neugarten J, Bellin E, et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. *JASN*. 2020;31(9):2145-2157. doi:10.1681/ASN.2020040509
9. Zahid U, Ramachandran P, Spitalewitz S, et al. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications. *Am J Nephrol*. 2020;51(10):786-796. doi:10.1159/000511160
10. Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. *JASN*. 2021;32(1):151-160. doi:10.1681/ASN.2020050615
11. Smilowitz NR, Nguy V, Aphinyanaphongs Y, et al. Multiple Biomarker Approach to Risk Stratification in COVID-19. *Circulation*. Published online February 15, 2021:CIRCULATIONAHA.120.053311. doi:10.1161/CIRCULATIONAHA.120.053311

12. *KDIGO Clinical Practice Guideline for Acute Kidney Injury*. Kidney Disease Improving Global Outcomes; 2012:1-141. Accessed January 8, 2021. <https://linkinghub.elsevier.com/retrieve/pii/S2157171615310388>
13. Hu F-C. My.stepwise.coxph, Stepwise Variable Selection Procedure For Cox's Proportional Hazards Model And Cox's Model. R Documentation. Accessed February 23, 2021. <https://www.rdocumentation.org/packages/My.stepwise/versions/0.1.0/topics/My.stepwise.coxph>
14. McGee S. Simplifying likelihood ratios. *J Gen Intern Med*. 2002;17(8):647-650. doi:10.1046/j.1525-1497.2002.10750.x
15. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719
16. Rubin DB. Inference and Missing Data. *Biometrika*. 1976;63(3):581-592.
17. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious Diseases*. 2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7
18. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ*. Published online November 27, 2020:m4509. doi:10.1136/bmj.m4509
19. Signorelli C, Odone A. Age-specific COVID-19 case-fatality rate: no evidence of changes over time. *Int J Public Health*. 2020;65(8):1435-1436. doi:10.1007/s00038-020-01486-0
20. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol*. 2020;35(12):1123-1138. doi:10.1007/s10654-020-00698-1
21. Martin SE, Mathur R, Marshall I, Douglas NJ. The effect of age, sex, obesity and posture on upper airway size. *European Respiratory Journal*. 1997;10(9):2087-2090. doi:10.1183/09031936.97.10092087
22. Svartengren M. Long-term clearance from small airways decreases with age. *European Respiratory Journal*. 2005;26(4):609-615. doi:10.1183/09031936.05.00002105
23. Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. *Aging Clin Exp Res*. 2020;32(8):1599-1608. doi:10.1007/s40520-020-01631-y

- 1  
2  
3 1 24. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of  
4 2 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy  
5 3 Region, Italy. *JAMA*. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394  
6  
7  
8 4 25. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of  
9 5 Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 —  
10 6 COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep*.  
11 7 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3  
12  
13 8 26. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the  
14 9 controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur Respir*  
15 10 *J*. 2020;56(4). doi:10.1183/13993003.03006-2020  
16  
17  
18 11 27. Han SS, Baek SH, Ahn SY, et al. Anemia Is a Risk Factor for Acute Kidney Injury  
19 12 and Long-Term Mortality in Critically Ill Patients. *Tohoku J Exp Med*.  
20 13 2015;237(4):287-295. doi:10.1620/tjem.237.287  
21  
22 14 28. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,  
23 15 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-  
24 16 19): A Review. *JAMA*. 2020;324(8):782. doi:10.1001/jama.2020.12839  
25  
26  
27 17 29. Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and  
28 18 mortality in COVID-19 patients: a case control study. *J Intensive Care*. 2020;8.  
29 19 doi:10.1186/s40560-020-00466-z  
30  
31 20 30. Lindner G, Funk G-C, Pfortmueller CA, et al. D-dimer to Rule Out Pulmonary  
32 21 Embolism in Renal Insufficiency. *The American Journal of Medicine*.  
33 22 2014;127(4):343-347. doi:10.1016/j.amjmed.2013.12.003  
34  
35  
36 23 31. Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the  
37 24 need for mechanical ventilation in COVID-19. *Journal of Allergy and Clinical*  
38 25 *Immunology*. 2020;146(1):128-136. doi:10.1016/j.jaci.2020.05.008  
39  
40 26 32. Laguna-Goya R, Utrero-Rico A, Talayero P, et al. IL-6–based mortality risk model  
41 27 for hospitalized patients with COVID-19. *Journal of Allergy and Clinical*  
42 28 *Immunology*. 2020;146(4):799-807.e9. doi:10.1016/j.jaci.2020.07.009  
43  
44  
45  
46  
47  
48 30  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Figure Legends**  
4

5 **2 Fig. 1 Receiver Operating Characteristics and Kaplan Meier Event Curves Using**  
6 **3 Selected Variables.**  
7

8 **(A)** Receiver operating characteristic (ROC) curves for acute kidney injury (AKI) within 3  
9 days and death within 30 days using fully adjusted model coefficients and developed  
10 risk score. Each line represents a different model's predictions with the given variables.  
11 HGB = Hemoglobin, CRP = C-reactive protein, WBC = white blood cell, PLT = Platelets.  
12  
13

14 **(B)** Kaplan-Meier event curves for AKI events and death events stratified by AKI and  
15 death scores. Time begins at positive COVID-19 test.  
16  
17

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 **Table 1.** Characteristics of Patients with Acute Kidney Injury, Patients that Died, and All  
 2 Patients.

Variable, n (%)	AKI (n=696)	Died (n=347)	Total (n=3,716)
Age (years)			
<45	86 (12.4)	7 (2.0)	980 (26.4)
45-65	245 (35.2)	55 (15.9)	1,310 (35.3)
>65	365 (52.4)	285 (82.1)	1,426 (38.4)
Sex (Male)	420 (60.3)	202 (58.2)	1,855 (49.9)
Race			
White	407 (58.5)	242 (69.7)	2,091 (56.3)
Black	110 (15.8)	50 (14.4)	568 (15.3)
Hispanic	22 (3.2)	9 (2.6)	135 (3.6)
Asian	27 (3.9)	8 (2.3)	140 (3.8)
Other	130 (18.7)	38 (11.0)	782 (21.0)
Diabetes	197 (28.3)	87 (25.1)	727 (19.6)
Cardiovascular Disease	67 (9.6)	49 (14.1)	231 (6.2)
Hypertension	135 (19.4)	65 (18.7)	484 (13.0)
Heart Failure	39 (5.6)	38 (11.0)	134 (3.6)
Medical Conditions (number)			
0	397 (57.0)	189 (54.5)	2,565 (69.0)
1	190 (27.3)	95 (27.4)	811 (21.8)
2	83 (11.9)	47 (13.5)	264 (7.1)
3+	26 (3.7)	16 (4.6)	76 (2.0)
Body Mass Index (kg/m <sup>2</sup> )			
<25	165 (23.7)	115 (33.1)	833 (22.4)
25-30	229 (32.9)	110 (31.7)	1,334 (35.9)
>30	302 (43.4)	122 (35.2)	1,549 (41.7)
Temperature (F)			
97-100.4	423 (60.8)	201 (57.9)	2,745 (73.9)
<97	35 (5.0)	22 (6.3)	190 (5.1)
>100.4	238 (34.2)	124 (35.7)	781 (21.0)
Heart Rate (beats/min)			
60-110	576 (82.8)	274 (79.0)	3,194 (86.0)
<60	61 (8.8)	30 (8.6)	275 (7.4)
>110	59 (8.5)	43 (12.4)	247 (6.6)
Systolic Blood Pressure (mmHg)			
90-180	635 (91.2)	305 (87.9)	3,549 (95.5)
<90	48 (6.9)	35 (10.1)	117 (3.1)
>180	13 (1.9)	7 (2.0)	50 (1.3)
Respiratory Rate (per minute)			

<20	245 (35.2)	92 (26.5)	1,692 (45.5)
>20	364 (52.3)	202 (58.2)	1,237 (33.3)
NA (Missing)	87 (12.5)	53 (15.3)	787 (21.2)
White Blood Cell (thousand cells/mm <sup>3</sup> )			
3.5-11	428 (61.5)	189 (54.5)	2,942 (79.2)
<3.5	39 (5.6)	26 (7.5)	267 (7.2)
>11	229 (32.9)	132 (38.0)	507 (13.6)
Hemoglobin (g/dL)			
12+	201 (28.9)	138 (39.8)	2,250 (60.5)
10-12	204 (29.3)	88 (25.4)	883 (23.8)
<10	291 (41.8)	121 (34.9)	583 (15.7)
Platelets (per $\mu$ L)			
>100	643 (92.4)	310 (89.3)	3,600 (96.9)
<100	53 (7.6)	37 (10.7)	116 (3.1)
C-Reactive Protein (mg/L)			
<50	197 (28.3)	62 (17.9)	1,706 (45.9)
50-100	149 (21.4)	63 (18.2)	1,011 (27.2)
>100	350 (50.3)	222 (64.0)	999 (26.9)
Ferritin ( $\mu$ g/L)			
<250	105 (15.1)	52 (15.0)	950 (25.6)
250-1000	327 (47.0)	155 (44.7)	1,894 (51.0)
>1000	264 (37.9)	140 (40.3)	872 (23.5)
D-Dimer (ng/mL)			
<1000	136 (19.5)	60 (17.3)	1,726 (46.4)
1000-2000	217 (31.2)	101 (29.1)	1,076 (29.0)
>2000	343 (49.3)	186 (53.6)	914 (24.6)
Interleukin-6 (IU/mL)			
<40	121 (17.4)	26 (7.5)	438 (11.8)
40-80	68 (9.8)	33 (9.5)	137 (3.7)
>80	136 (19.5)	58 (16.7)	196 (5.3)
NA (Missing)	371 (53.3)	230 (66.3)	2,945 (79.3)

AKI = acute kidney injury

1 **Table 2.** Multivariable Cox Regression Results.

Variable	AKI	Death
Age (years)		
<45	Reference	Reference
45-65	<b>1.71 (1.33, 2.21)</b>	<b>5.33 (2.42, 11.8)</b>
>65	<b>2.16 (1.66, 2.80)</b>	<b>23.4 (10.9, 50.1)</b>
Sex (Male)	<b>1.51 (1.28, 1.77)</b>	1.16 (0.92, 1.45)
Race		
White	Reference	Reference
Black	0.89 (0.72, 1.11)	<b>0.66 (0.48, 0.92)</b>
Hispanic	0.89 (0.58, 1.38)	0.62 (0.32, 1.23)
Asian	0.96 (0.65, 1.43)	<b>0.46 (0.22, 0.93)</b>
Other	1.11 (0.90, 1.37)	0.72 (0.50, 1.02)
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.28 (1.07, 1.53)</b>	<b>1.07 (0.83, 1.38)</b>
2	<b>1.67 (1.30, 2.13)</b>	<b>1.40 (1.01, 1.95)</b>
3+	<b>1.82 (1.21, 2.75)</b>	<b>1.61 (0.95, 2.73)</b>
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.09 (0.89, 1.33)	0.78 (0.59, 1.02)
>30	<b>1.42 (1.17, 1.74)</b>	0.94 (0.72, 1.22)
Temperature (F)		
97-100.4	Reference	Reference
<97	1.07 (0.75, 1.51)	1.18 (0.75, 1.85)
>100.4	<b>1.59 (1.34, 1.88)</b>	<b>1.54 (1.22, 1.96)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.24 (0.95, 1.63)	0.97 (0.66, 1.43)
>110	1.11 (0.85, 1.47)	<b>1.78 (1.28, 2.48)</b>
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.90 (1.41, 2.57)</b>	<b>2.10 (1.45, 3.04)</b>
>180	0.96 (0.55, 1.67)	0.90 (0.42, 1.92)
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.78 (0.55, 1.09)	1.10 (0.72, 1.68)
>11	<b>1.77 (1.49, 2.12)</b>	<b>2.32 (1.82, 2.95)</b>
Hemoglobin (g/dL)		
>12	Reference	Reference
10-12	<b>2.15 (1.75, 2.64)</b>	0.88 (0.67, 1.16)
<10	<b>3.72 (3.03, 4.57)</b>	1.03 (0.78, 1.35)

Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.74 (1.30, 2.34)</b>	<b>2.60 (1.79, 3.77)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.96 (0.77, 1.20)	<b>1.46 (1.02, 2.10)</b>
>100	<b>1.57 (1.29, 1.91)</b>	<b>3.61 (2.65, 4.93)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	<b>1.29 (1.03, 1.63)</b>	0.91 (0.65, 1.26)
>1000	<b>1.69 (1.31, 2.17)</b>	1.14 (0.80, 1.62)
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.67 (1.33, 2.09)</b>	1.21 (0.87, 1.69)
>2000	<b>2.11 (1.68, 2.65)</b>	<b>1.82 (1.31, 2.52)</b>

1

1 **Table 3.** Risk Score and Internal Validation Results.

AKI in 3 days (max 6)		Death in 30 days (max 7)	
Risk Score			
Variable	Value	Variable	Value
Hemoglobin <10 g/dL	2	Age > 65 years	3
Hemoglobin 10-12 g/dL	1	Age 45-65 years	2
D-Dimer > 1,000 ng/mL	1	CRP > 100 mg/L	1
CRP > 100 mg/L	1	Platelets < 100 per $\mu$ L	1
WBC > 11,000 cells/mm <sup>3</sup>	1	WBC > 11,000 cells/mm <sup>3</sup>	1
Male Sex	1	D-Dimer > 2,000 ng/mL	1
Internal Validation			
Validation Type	AUC (95% intervals)	Validation Type	AUC (95% intervals)
Whole Data	0.785 (0.758, 0.813)	Whole Data	0.861 (0.843, 0.878)
Cross Validation	0.776 (0.732, 0.816)	Cross Validation	0.860 (0.831, 0.886)

2 CRP = C-reactive protein, WBC = white blood cells.

3 Whole data validation presents area under the curve (AUC) estimates and 95%  
4 confidence intervals.

5 Internal cross validation presents mean AUC and 95% central interval (2.5<sup>th</sup> and 97.5<sup>th</sup>  
6 percentiles).

7


1 **Table 4.** Suggested Risk Stratification Cutoffs and Observed and Estimated Event  
 2 Rates.

<b>AKI Risk Score</b>				
<b>Risk Level</b>	<b>Total Score</b>	<b>Observed Total AKI (%)</b>	<b>Estimated 3 Day AKI (%)</b>	<b>Estimated 30 Day AKI (%)</b>
Low Risk	0-1	5.2	1.7	5.4
Moderate Risk	2-3	18.4	6.2	19.7
High Risk	4-6	54.7	21.6	59.7
<b>Death Risk Score</b>				
<b>Risk Level</b>	<b>Total Score</b>	<b>Observed Total Death (%)</b>	<b>Estimated 30 Day Death (%)</b>	<b>Estimated 60 Day Death (%)</b>
Low Risk	0-3	1.7	1.6	2.0
Moderate Risk	4	10.4	10.2	12.3
High Risk	5-7	37.9	37.3	43.4

3 Observed percentages are from the observed data

4 Estimated percentages are from Kaplan-Meier event curves

5



(A) Receiver operating characteristic (ROC) curves for acute kidney injury (AKI) within 3 days and death within 30 days using fully adjusted model coefficients and developed risk score. Each line represents a different model's predictions with the given variables. HGB = Hemoglobin, CRP = C-reactive protein, WBC = white blood cell, PLT = Platelets.

(B) Kaplan-Meier event curves for AKI events and death events stratified by AKI and death scores. Time begins at positive COVID-19 test.

450x448mm (96 x 96 DPI)

## Supplemental Methods – Additional Details

### *Statistical Analyses*

Descriptive statistics and receiver operating characteristics (ROC) were calculated using R base functions. Cox proportional hazards models were fit using the “survival” package. Inspection of AKI and death Kaplan-Meier event curves stratified by each variable revealed no obvious violations of the proportional hazards assumption.

The variable selection procedure was implemented using the “My.stepwise” package. In addition to the variables included in fully adjusted Cox proportional hazards models, age >45 years, medical conditions >1, medical conditions >2, BMI > 25 kg/m<sup>2</sup>, hemoglobin <12 g/dL, CRP > 500 mg/L, ferritin >250 µg/L, and D-Dimer > 1,000 ng/mL were also included. The package “glmnet” was used to reformat data so that the variable selection procedure could be applied. The selection procedure alternates between “forward” steps of adding variables and “backwards” steps of removing variables. The significance level for entry and for staying was conservatively set at 0.15 as suggested by function details. The top 5 variables (top 6 dummy variables) were included in risk scores. Simplified risk score values were obtained by rounding model coefficients to the nearest integer.

ROC curves were created using “plotROC” and AUC values and confidence intervals were obtained from “pROC”. Event curves were created using “survminer” and “mstate”. Harrell’s C-statistics were obtained from Cox proportional hazards model output, and net reclassification of improvement was obtained from “nricens”.



1  
2  
3                   Competing risk analyses used the “cmprsk” package, and multiple imputation  
4  
5 analyses used the “mice” package. The packages “ggplot2”, “dplyr”, “plyr”, “ggfortify”,  
6  
7 and “cowplot” were used to process results and create figures. Code for replicating all  
8  
9 analyses will be available online.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table S1.** Coefficients from simplified Cox regression models to calculated and internal validation statistics using these coefficient linear predictions.

AKI		Death	
Simplified Model Coefficients			
Variable	Coefficient Value	Variable	Coefficient Value
Hemoglobin <10 g/dL	1.50	Age > 65 years	3.19
Hemoglobin 10-12 g/dL	0.85	Age 45-65 years	1.65
D-Dimer > 1,000 ng/mL	0.76	CRP > 100 mg/L	1.21
CRP > 100 mg/L	0.64	Platelets < 100 per $\mu$ L	1.20
WBC > 11,000 cells/mm <sup>3</sup>	0.59	WBC > 11,000 cells/mm <sup>3</sup>	0.87
Male Sex	0.54	D-Dimer > 2,000 ng/mL	0.58
Internal Validation			
Statistic	Estimate (95% CI)	Statistic	Estimate (95% CI)
Harrell's Survival C-Statistic (Concordance)	0.785 (0.769, 0.800)	Harrell's Survival C-Statistic (Concordance)	0.857 (0.841, 0.874)
AKI in 3 Days AUC	0.787 (0.759, 0.814)	Death in 30 Days AUC	0.872 (0.854, 0.890)

AKI = acute kidney injury, CRP = C-reactive protein, WBC = white blood cells, AUC = area under the curve, CI = confidence interval

**Table S2.** Coefficients from fully adjusted Cox regression models and internal validation statistics using these coefficient linear predictions.

AKI		Death	
Fully Adjusted Model Coefficients			
Variable	Coefficient Value	Variable	Coefficient Value
Age 45-65 years	0.54	Age 45-65 years	1.67
Age > 65 years	0.77	Age > 65 years	3.15
Male Sex	0.41	Male Sex	0.14
Race Black	-0.12	Race Black	-0.41
Race Hispanic	-0.12	Race Hispanic	-0.47
Race Asian	-0.04	Race Asian	-0.79
Race Other	0.11	Race Other	-0.33
Medical Conditions 1	0.25	Medical Conditions 1	0.07
Medical Conditions 2	0.51	Medical Conditions 2	0.34
Medical Conditions 3+	0.60	Medical Conditions 3+	0.48
BMI 25-30 kg/m <sup>2</sup>	0.08	BMI 25-30 kg/m <sup>2</sup>	-0.25
BMI >30 kg/m <sup>2</sup>	0.35	BMI >30 kg/m <sup>2</sup>	-0.06
Temp < 97 F	0.06	Temp < 97 F	0.16
Temp > 100.4 F	0.46	Temp > 100.4 F	0.43
Heart rate < 60 beats/min	0.22	Heart rate < 60 beats/min	-0.03
Heart rate < 110 beats/min	0.11	Heart rate < 110 beats/min	0.58
SBP < 90 mmHg	0.64	SBP < 90 mmHg	0.74
SBP > 180 mmHg	-0.04	SBP > 180 mmHg	-0.11
WBC < 3,500 cells/mm <sup>3</sup>	-0.25	WBC < 3,500 cells/mm <sup>3</sup>	0.09
WBC > 11,000 cells/mm <sup>3</sup>	0.57	WBC > 11,000 cells/mm <sup>3</sup>	0.84
Hemoglobin <10 g/dL	0.77	Hemoglobin <10 g/dL	-0.13
Hemoglobin 10-12 g/dL	1.31	Hemoglobin 10-12 g/dL	0.03
Platelets < 100 per $\mu$ L	0.56	Platelets < 100 per $\mu$ L	0.96
CRP 50-100 mg/L	-0.04	CRP 50-100 mg/L	0.38
CRP > 100 mg/L	0.45	CRP > 100 mg/L	1.28
Ferritin 250-1000 $\mu$ g/L	0.26	Ferritin 250-1000 $\mu$ g/L	-0.10
Ferritin >1000 $\mu$ g/L	0.52	Ferritin >1000 $\mu$ g/L	0.13
D-Dimer 1,000-2,000 ng/mL	0.51	D-Dimer 1,000-2,000 ng/mL	0.19
D-Dimer > 2,000 ng/mL	0.75	D-Dimer > 2,000 ng/mL	0.60
Internal Validation			

<b>Statistic</b>	<b>Estimate (95% CI)</b>	<b>Statistic</b>	<b>Estimate (95% CI)</b>
Harrell's Survival C-Statistic (Concordance)	0.813 (0.798, 0.827)	Harrell's Survival C-Statistic (Concordance)	0.878 (0.863, 0.892)
AKI in 3 Days AUC	0.820 (0.794, 0.845)	Death in 30 Days AUC	0.893 (0.878, 0.909)

For peer review only

**Table S3.** Sensitivity, specificity, and likelihood ratios (LR) for positive and negative results of risk scores predicting acute kidney injury (AKI) within 3 days and death within 30 days of a positive COVID-19 test.

Cutoff	Sensitivity	Specificity	Positive LR	Negative LR
<b>Simplified AKI Risk Score (max 6)</b>				
<b>Rule in</b>				
0	1.000	0.000	1.000	NA
1	0.992	0.154	1.170	0.050
2	0.892	0.455	1.640	0.240
3	0.759	0.713	2.640	0.340
4	0.526	0.860	3.750	0.550
5	0.257	0.946	4.770	0.790
6	0.068	0.989	6.400	0.940
7	0.000	1.000	NA	1.000
<b>Simplified Death Risk Score (max 7)</b>				
0	1.000	0.000	1.000	NA
1	1.000	0.156	1.190	0.000
2	0.994	0.233	1.300	0.030
3	0.984	0.433	1.740	0.040
4	0.891	0.665	2.660	0.160
5	0.637	0.890	5.760	0.410
6	0.224	0.978	10.400	0.790
7	0.019	1.000	Inf	0.980
8	0.000	1.000	NA	1.000

Cutoff denotes treating a score greater than or equal a cutoff value as a positive.

Positive likelihood ratio (LR) is sensitivity / (1-specificity)

Negative likelihood ratio (LR) is (1-sensitivity) / specificity

Sensitivity 1 specificity 0 indicates all individuals identified as positive

Sensitivity 0 specificity 1 indicates all individuals identified as negative

Approximate probability changes can be obtained by  $\approx 0.18 * \ln(\text{LR})$  (McGee 2002)

**Table S4.** Multivariable AKI cause-specific hazard (AKI event, death censor) and AKI subdistribution hazard (AKI and death competing risks) model results.

Variable	Cause-Specific	Subdistribution
Age (years)		
<45	Reference	Reference
45-65	<b>1.71 (1.33, 2.21)</b>	<b>1.67 (1.31, 2.14)</b>
>65	<b>2.16 (1.66, 2.80)</b>	<b>1.92 (1.48, 2.50)</b>
Sex (Male)	<b>1.51 (1.28, 1.77)</b>	<b>1.53 (1.29, 1.81)</b>
Race		
White	Reference	Reference
Black	0.89 (0.72, 1.11)	0.91 (0.73, 1.14)
Hispanic	0.89 (0.58, 1.38)	0.96 (0.65, 1.41)
Asian	0.96 (0.65, 1.43)	0.97 (0.67, 1.41)
Other	1.11 (0.90, 1.37)	1.13 (0.91, 1.40)
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.28 (1.07, 1.53)</b>	<b>1.27 (1.06, 1.53)</b>
2	<b>1.67 (1.30, 2.13)</b>	<b>1.66 (1.29, 2.12)</b>
3+	<b>1.82 (1.21, 2.75)</b>	<b>1.81 (1.18, 2.77)</b>
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.09 (0.89, 1.33)	1.11 (0.90, 1.38)
>30	<b>1.42 (1.17, 1.74)</b>	<b>1.47 (1.19, 1.81)</b>
Temperature (F)		
97-100.4	Reference	Reference
<97	1.07 (0.75, 1.51)	1.03 (0.71, 1.48)
>100.4	<b>1.59 (1.34, 1.88)</b>	<b>1.62 (1.37, 1.91)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.24 (0.95, 1.63)	1.30 (0.98, 1.72)
>110	1.11 (0.85, 1.47)	1.04 (0.78, 1.38)
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.90 (1.41, 2.57)</b>	<b>1.73 (1.28, 2.35)</b>
>180	0.96 (0.55, 1.67)	1.00 (0.55, 1.84)
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.78 (0.55, 1.09)	0.79 (0.56, 1.12)
>11	<b>1.77 (1.49, 2.12)</b>	<b>1.68 (1.39, 2.04)</b>
Hemoglobin (g/dL)		
>12	Reference	Reference
10-12	<b>2.15 (1.75, 2.64)</b>	<b>2.27 (1.83, 2.81)</b>

<10	<b>3.72 (3.03, 4.57)</b>	<b>3.94 (3.17, 4.90)</b>
Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.74 (1.30, 2.34)</b>	<b>1.63 (1.19, 2.24)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.96 (0.77, 1.20)	0.94 (0.76, 1.18)
>100	<b>1.57 (1.29, 1.91)</b>	<b>1.48 (1.20, 1.82)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	<b>1.29 (1.03, 1.63)</b>	<b>1.33 (1.05, 1.69)</b>
>1000	<b>1.69 (1.31, 2.17)</b>	<b>1.70 (1.31, 2.21)</b>
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.67 (1.33, 2.09)</b>	<b>1.70 (1.36, 2.13)</b>
>2000	<b>2.11 (1.68, 2.65)</b>	<b>2.07 (1.63, 2.63)</b>

**Table S5.** Multiple Imputation Multivariable Cox Regression Results.

Variable	AKI	Death
Age (years)		
<45	Reference	Reference
45-65	<b>1.58 (1.22, 2.04)</b>	<b>4.60 (2.07, 10.3)</b>
>65	<b>1.86 (1.43, 2.43)</b>	<b>18.3 (8.47, 39.6)</b>
Sex (Male)	<b>1.42 (1.20, 1.68)</b>	1.05 (0.83, 1.33)
Race		
White	Reference	Reference
Black	0.87 (0.69, 1.08)	<b>0.65 (0.47, 0.89)</b>
Hispanic	0.97 (0.63, 1.50)	0.66 (0.33, 1.32)
Asian	0.92 (0.61, 1.38)	<b>0.39 (0.19, 0.80)</b>
Other	1.05 (0.85, 1.30)	<b>0.67 (0.47, 0.96)</b>
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.32 (1.10, 1.58)</b>	1.07 (0.82, 1.39)
2	<b>1.62 (1.25, 2.09)</b>	1.33 (0.94, 1.89)
3+	<b>1.88 (1.24, 2.87)</b>	1.62 (0.94, 2.79)
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.10 (0.90, 1.36)	0.81 (0.61, 1.07)
>30	<b>1.33 (1.09, 1.63)</b>	0.86 (0.65, 1.13)
Temperature (F)		
97-100.4	Reference	Reference
<97	0.95 (0.66, 1.36)	1.11 (0.69, 1.77)
>100.4	<b>1.40 (1.18, 1.66)</b>	<b>1.40 (1.09, 1.81)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.13 (0.86, 1.48)	0.86 (0.58, 1.30)
>110	0.98 (0.74, 1.31)	1.41 (0.95, 2.08)
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.74 (1.28, 2.37)</b>	<b>1.76 (1.19, 2.60)</b>
>180	1.22 (0.68, 2.19)	1.16 (0.52, 2.55)
Respiratory Rate (per minute)		
<20	Reference	Reference
>20	<b>1.72 (1.45, 2.03)</b>	<b>1.98 (1.53, 2.55)</b>
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.81 (0.58, 1.15)	1.25 (0.81, 1.95)
>11	<b>1.61 (1.34, 1.93)</b>	<b>1.95 (1.52, 2.51)</b>
Hemoglobin (g/dL)		



>12	Reference	Reference
10-12	<b>2.02 (1.64, 2.49)</b>	0.81 (0.60, 1.09)
<10	<b>3.31 (2.68, 4.08)</b>	0.86 (0.65, 1.14)
Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.85 (1.37, 2.49)</b>	<b>2.51 (1.72, 3.68)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.99 (0.79, 1.24)	<b>1.60 (1.10, 2.33)</b>
>100	<b>1.47 (1.20, 1.80)</b>	<b>3.18 (2.32, 4.37)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	1.18 (0.93, 1.50)	0.77 (0.54, 1.12)
>1000	<b>1.48 (1.14, 1.91)</b>	0.89 (0.60, 1.32)
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.59 (1.27, 2.00)</b>	1.16 (0.82, 1.63)
>2000	<b>2.03 (1.60, 2.57)</b>	<b>1.73 (1.23, 2.44)</b>
Interleukin-6 (IU/mL)		
<40	Reference	Reference
40-80	<b>1.39 (1.03, 1.86)</b>	<b>2.75 (1.80, 4.21)</b>
>80	<b>1.91 (1.50, 2.43)</b>	<b>3.07 (2.01, 4.69)</b>

Pooled hazard ratios calculated using 10 different imputation datasets with imputed values for missing respiratory rate and IL-6.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7-8 7-8 7-8 7-8 7-8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
10				
11	<b>Discussion</b>			
12				
13	Key results	18	Summarise key results with reference to study objectives	12-14
14				
15	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
18				
19				
20	Generalisability	21	Discuss the generalisability (external validity) of the study results	15
21				
22	<b>Other information</b>			
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16
24				
25				

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

## Risk Assessment for Acute Kidney Injury and Death among New COVID-19 Positive Adult Patients without Chronic Kidney Disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053635.R1
Article Type:	Original research
Date Submitted by the Author:	06-Nov-2021
Complete List of Authors:	Li, Daniel; Harvard University T H Chan School of Public Health; Johns Hopkins School of Medicine Ren, Hui; Harvard Medical School, Department of Radiology Varelmann, Dirk J.; Brigham and Women's Hospital, Department of Anesthesiology Sarin, Pankaj; Brigham and Women's Hospital, Department of Anesthesiology Xu, Pengcheng; Harvard Medical School, Department of Radiology Wu, Dufan; Harvard Medical School, Department of Radiology Li, Quanzheng; Harvard Medical School, Department of Radiology Lin, Xihong; Harvard University T H Chan School of Public Health, Department of Biostatistics; Harvard University, Department of Statistics
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Research methods, Health informatics
Keywords:	COVID-19, EPIDEMIOLOGY, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 1 **Title Page**  
4  
5 2

6 3 **Risk Assessment for Acute Kidney Injury and Death among New COVID-19**  
7 4 **Positive Adult Patients without Chronic Kidney Disease: Retrospective Cohort**  
8 5 **Study among 3 US Hospitals**  
9 6

10 7 *Short Title:* AKI and Death among COVID-19 Patients without CKD  
11 8

12 9 Daniel Li, MD, MA,<sup>1,2\*</sup> Hui Ren, MD, PhD, MPH<sup>3\*</sup> Dirk J. Varelmann, MD,<sup>4</sup> Pankaj Sarin,  
13 10 MD,<sup>4</sup> Pengcheng Xu, BS,<sup>3</sup> Dufan Wu, PhD,<sup>3</sup> Quanzheng Li, PhD,<sup>3\*\*</sup> Xihong Lin,  
14 11 PhD<sup>1,5,6\*\*</sup>  
15  
16  
17

18 12 \*Contributed equally, co-first authorship  
19

20 13 <sup>1</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston MA.  
21

22 14 <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore MD.  
23

24 15 <sup>3</sup>Department of Radiology, Massachusetts General Hospital and Harvard Medical  
25 16 School, Boston MA.

26 17 <sup>4</sup>Department of Anesthesiology, Brigham and Women's Hospital, Boston MA.  
27

28 18 <sup>5</sup>Department of Statistics, Harvard University, Cambridge MA.  
29

30 19 <sup>6</sup>Broad Institute of MIT and Harvard, Cambridge, MA.  
31  
32

33 21 **\*\*Correspondence:** Xihong Lin, Quanzheng Li  
34

35 22 Department of Biostatistics  
36

37 23 655 Huntington Ave  
38

39 24 Building II, Room 419  
40

41 25 Boston, MA 02115  
42

43 26 Telephone: 617 432 2914  
44

45 27 Fax: 617 432 5619  
46

47 28 **Email:** [xlin@hsph.harvard.edu](mailto:xlin@hsph.harvard.edu), [li.quanzheng@mgh.harvard.edu](mailto:li.quanzheng@mgh.harvard.edu)  
48  
49

50 30 Abstract 277 words; Main Text 3,138 words; References 32; Tables 4; Figures 1;  
51

52 31 Appendix Tables 5  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **Abstract**

2 **Objective:** To develop simple but clinically informative risk stratification tools using a  
3 few top demographic factors and biomarkers at COVID-19 diagnosis to predict acute  
4 kidney injury (AKI) and death.

5 **Design:** Retrospective cohort analysis, follow-up from February 1 through May 28,  
6 2020.

7 **Setting:** 3 teaching hospitals, 2 urban and 1 community-based in the Boston area.

8 **Participants:** Eligible patients were at least 18 years old, tested COVID-19 positive  
9 from February 1 through May 28, 2020, and had at least two serum creatinine  
10 measurements within 30 days of a new COVID-19 diagnosis. Exclusion criteria were  
11 having CKD or having a previous AKI within 3 months of a new COVID-19 diagnosis.

12 **Main Outcomes and Measures:** Time from new COVID-19 diagnosis until AKI event,  
13 time until death event.

14 **Results:** Among 3,716 patients, there were 1,855 (49.9%) males and the average age  
15 was 58.6 years (SD 19.2 years). Age, sex, white blood cell, hemoglobin, platelet, C-  
16 reactive protein, and D-dimer levels were most strongly associated with AKI and/or  
17 death. We created risk scores using these variables predicting AKI within 3 days and  
18 death within 30 days of a new COVID-19 diagnosis. Area under the curve (AUC) for  
19 predicting AKI within 3 days was 0.785 (95% CI, 0.758 to 0.813) and AUC for death  
20 within 30 days was 0.861 (95% CI, 0.843 to 0.878). Hemoglobin was the most predictive  
21 component for AKI, and age the most predictive for death. Predictive accuracies using  
22 all study variables were similar to using the simplified scores.

1 **Conclusion:** Simple risk scores using age, sex, a complete blood cell count, C-reactive  
2 protein, and D-dimer were highly predictive of AKI and death and can help simplify and  
3 better inform clinical decision making.

4 **Key words:** COVID-19; kidney injury; risk prediction

### 6 **Strengths and limitations of this study**

- 7 • Various associations between patient variables and COVID-19 acute kidney  
8 injury AKI and death have been reported, but it is unclear which variables are  
9 most predictive and important to focus on.
- 10 • We developed risk scores for predicting AKI and death among new COVID-19  
11 positive patients.
- 12 • Readily obtainable demographic, vital sign, and laboratory values were  
13 considered evaluated.
- 14 • Findings are limited to patients without chronic kidney disease.



## 1 Introduction

2 Although respiratory failure and diffuse inflammatory lung tissue damage are key  
3 features of coronavirus disease 2019 (COVID-19), involvement of other organs such as  
4 the kidneys has been well documented. Pathologic autopsy examinations of COVID-19  
5 kidneys have shown clusters of coronavirus-like particles in the tubular epithelium and  
6 podocytes, upregulation of the severe acute respiratory syndrome coronavirus 2  
7 (SARS-CoV-2) receptor angiotensin-converting enzyme 2 and positive immunostaining  
8 with SARS-CoV-2 nucleoprotein antibodies.<sup>1,2</sup> Hemodynamic instability, systemic  
9 hypoxia, abnormal coagulation, and inflammation from severe COVID-19 can also  
10 directly contribute to acute kidney injury (AKI) and induce acute tubular necrosis.<sup>3</sup>

11 Various epidemiologic studies from China, Europe, and the United States have  
12 investigated AKI outcomes among COVID-19 patients. Early studies in China have  
13 reported AKI incidences ranging from 0.5-15% among hospitalized and outpatient  
14 COVID-19 patients.<sup>4,5</sup> One United Kingdom study found hospitalized COVID-19 patients  
15 with AKI had a 3-fold higher odds of death than those without AKI.<sup>6</sup> Large US population  
16 studies of hospitalized COVID-19 patients, primarily in the New York City metropolitan  
17 area, have reported AKI incidences ranging from 27-57%, with in-hospital mortality rates  
18 ranging from 35-71% among AKI COVID-19 patients.<sup>7-10</sup> Some of these studies have  
19 also explored variable associations with COVID-19 AKI, but none of these studies have  
20 investigated which subset of these variables are most predictive of AKI or built risk  
21 predictions models using demographic variables and biomarkers.

22 Risk prediction tools have been investigated for COVID-19 deaths. A small  
23 number of a priori determined biomarkers were investigated for their associations with

1 the risk of COVID-19 death.<sup>11</sup> However, a more data driven approach would compare  
2 the predictive accuracies of these biomarkers to other biomarkers and variables such as  
3 demographic factors and vital signs and build a more powerful risk prediction model  
4 using a comprehensive set of biomarkers, demographic variables, and vital signs.  
5 Different risk factors should also be weighted differently, and understanding the relative  
6 importance of different variables in predicting poor outcomes will allow for more  
7 accurate holistic patient evaluations.

8 In this study we developed and evaluated new risk assessment tools that can be  
9 easily implemented at the bedside or during chart reviews to predict AKI and death after  
10 a positive COVID-19 test. Our contributions include (1) identifying the top biomarkers  
11 and demographic variables that predict AKI events among COVID-19 patients, (2)  
12 investigating a greater number of potential biomarkers and risk factors in predicting  
13 death, (3) developing clinical risk assessment tools for both AKI and death using a small  
14 number of predictors, and (4) validating that these tools are nearly as predictive as  
15 using all available study variables. By understanding which subset of risk factors are  
16 most important to focus on, medical providers can more efficiently work up and risk  
17 stratify their newly diagnosed COVID-19 patients.

## 18 19 **Methods**

### 20 *Study Population*

21 The Mass General Brigham (MGB) Health system serves a large diverse patient  
22 population around Boston and Eastern Massachusetts. Electronic health records from

1 three major hospitals in this system (Massachusetts General Hospital in Boston,  
2 Brigham and Women's Hospital in Boston, and Newton-Wellesley Hospital in Newton)  
3 were used. The Mass General Brigham Institutional Review Board approved this study,  
4 and the approval number was 2020P001661. Patients and the public were not involved  
5 in the planning of this project.

6 We included all patients that 1) were at least 18 years old, 2) tested COVID-19  
7 positive at one of the three hospitals above between February 1, 2020 through May 28,  
8 2020, and 3) had at least 2 serum creatinine tests within 30 days of their SARS-Cov-2  
9 PCR test. We excluded patients that 1) met the criteria of acute kidney injury within 3  
10 months before their SARS-CoV-2 test and 2) had chronic kidney disease (CKD)  
11 identified as a preexisting condition from International Classification of Disease (ICD-9  
12 and ICD-10) codes (see below).

### 14 *Data Collection*

15 Information in electronic health records (EHR) of patients who met the inclusion  
16 criteria were extracted from the enterprise data warehouse and included demographic,  
17 comorbidities, clinical, laboratory, and outcome data (death). Demographic and  
18 laboratory data information closest to the time of first SARS-Cov-2 PCR test were kept  
19 (except for serum creatinine, multiple values were kept). Serum creatinine laboratory  
20 test results and timestamps within 3 months before and 30 days after the SARS-Cov-2  
21 polymerase chain reaction test were extracted. We categorized ethnic groups other than  
22 White, Black, Hispanic, and Asian into a single subgroup. All documented comorbidity

1 related medical history in MGB healthcare system enterprise data warehouse before the  
2 first time of SARS-Cov-2 test were extracted. Preexisting conditions, including  
3 hypertension, diabetes, cardiovascular disease, and heart failure, were classified using  
4 their ICD-9 or ICD-10 codes.

### 6 *Definitions of Outcomes*

7 Per the Kidney Disease Improving Global Outcomes (KDIGO) criteria, AKI was  
8 defined as a change in serum creatinine (SCr) of 0.3 mg/dl over a 48-hour period, a  
9 50% increase in baseline creatinine in 7 days, or urine value <0.5 ml/kg/hour for 6  
10 hours.<sup>12</sup> Due to difficulties obtaining accurate urine volumes from electronic health  
11 record data, we only use serum creatinine to define AKI events. If patients had more  
12 than 2 SCr tests in their EHR, we used all available SCr tests to define the earliest time.  
13 Death times were directly extracted from the data warehouse.

### 15 *Statistical Analyses*

16 Continuous variables were transformed into categorical variables to improve  
17 interpretability of results and account for nonlinear associations. Counts and  
18 percentages were presented, and two proportion z-tests were used to compare the  
19 proportion of deaths among AKI and non-AKI patients. For AKI survival analyses,  
20 observations without AKI were censored after 30 days, at the time of death, or at  
21 5/28/2020, whichever came first. For death survival analyses, observations without  
22 death were censored at 5/28/2020. Multiple multivariable Cox proportional hazards

1 models included age, sex, race, diabetes, cardiovascular disease, hypertension, heart  
2 failure, body mass index (BMI), temperature, heart rate, systolic blood pressure, white  
3 blood cell count (WBC), hemoglobin, platelets, C-reactive protein (CRP), ferritin, D-and  
4 dimer. Respiratory rate and interleukin-6 (IL-6) variables were not included in primary  
5 analyses given missing data. However, we performed exploratory analyses imputing the  
6 missing respiratory rate and IL-6 values (additional details are in the sensitivity analysis  
7 section).

8 We next built a simplified Cox model for clinical use by using a stepwise variable  
9 selection procedure for Cox models alternating between “forward” and “backwards”  
10 steps to identify the first 5 variables to be included.<sup>13</sup> Simplified Cox models were fit  
11 using only the selected 5 variables and Harrell’s C-Statistics were obtained (survival  
12 outcome). Model coefficient (linear prediction) accuracy was evaluated. We evaluated  
13 area under receive operating characteristic (ROC) curves (AUC) for predicting AKI  
14 within 3 days and death within 30 days of a new COVID-19 diagnosis (binary outcome).  
15 Net reclassification improvement (NRI) of adding all remaining covariates was also  
16 calculated.

17 Risk scores were obtained by rounding simplified model coefficients for easier  
18 clinical risk assessment use. For suggested risk score cutoffs, Kaplan-Meier event  
19 curves were plotted, log rank tests were performed, and sensitivities, specificities,  
20 positive and negative likelihood ratios were calculated. Approximate pre-test to post-test  
21 probability changes from likelihood ratios were calculated using the linear approximation  
22 proposed by McGee.<sup>14</sup> Cutoffs for low risk were chosen so that the negative likelihood  
23 ratio would be  $\approx 0.20$  with a pre- to post-test probability decrease of  $\approx 30\%$ , while cutoffs

1 for high risk were chosen so that the positive likelihood ratio would be  $\approx 5.0$  with a pre-  
2 post-test probability increase of  $\approx 30\%$  and that at least 15% of patients (560) would be  
3 identified as high risk.<sup>14</sup> We ran 1,000 internal cross validation iterations in which 70% of  
4 data were randomly assigned to training, the other 30% to testing. For each iteration,  
5 simplified Cox models were fit to the training data, coefficients were rounded to obtain  
6 risk scores, and AUC's were calculated using the predicted testing data risk scores.

7 We performed three sensitivity analyses. First, the multivariable cause-specific  
8 and subdistribution hazard to documented AKI events within 30 days accounting for the  
9 competing risk of death was modeled.<sup>15</sup> Second, we performed a multiple imputation  
10 analysis by creating 10 imputation datasets with imputed values for missing respiratory  
11 rate and IL-6 and then calculating pooled multivariable Cox hazard ratios.<sup>16</sup> Third, we  
12 investigated the AKI risk score accuracy in identifying stage 2 or 3 AKI as defined in the  
13 KDIGO criteria, and we investigated the death score accuracy among patients with  
14 stage 2 or 3 AKI.<sup>12</sup> All analyses were performed with R version 4.0.4 and all code for  
15 analyses are available online (to be posted during revisions).

## 17 Results

### 18 *Demographic and Clinical Characteristics*

19 There were 3,716 eligible adult COVID-19 positive patients without CKD, of  
20 which 1,855 (49.9%) were male. The average age was 58.6 years (SD 19.2 years).

21 There were 696 patients that developed AKI (18.7%) and 249 (35.8%) were within three  
22 days of a new COVID-19 diagnosis. There were 347 deaths (9.3%) and 322 (92.8%)

1 were within thirty days of a new COVID-19 diagnosis. Among the AKI group there were  
2 192 deaths (27.6%), and among the non-AKI group there were 155 deaths (5.1%,  
3  $p<0.001$ ). Patient demographics, preexisting conditions, vital signs, and laboratory  
4 values stratified by patients with AKI and patients that died are displayed in **Table 1**.  
5 Patients with AKI and patients that died were more likely to be older, male, have  
6 multiple comorbidities, and have on admission higher temperatures, lower systolic blood  
7 pressures, higher respiratory rates, elevated white blood cell counts, lower hemoglobin  
8 and platelets, and elevated CRP, ferritin, D-dimer, and IL-6 levels.

#### 9 10 *Fully Adjusted Multivariable Regression*

11 Multivariable Cox regression was performed to identify risk factors associated  
12 with time to AKI and death. **Table 2** displays pooled multivariable adjusted hazard  
13 ratios. Adjusting for all other variables, older age, increased medical conditions,  
14 increased temperature, decreased systolic blood pressure, increased white blood cells,  
15 decreased platelets, and increased CRP and D-Dimer were associated with increased  
16 hazards for both AKI and death. Elevated BMI, decreased hemoglobin, and increased  
17 ferritin were associated with increased hazards for AKI but not death. Black and Asian  
18 race were associated with decreased hazards and increased heart rate was associated  
19 with increased hazards for death but not AKI.

#### 20 21 *Top Risk Factor/Biomarker Selection*

1 The top five variables selected for being most associated with AKI events were  
2 hemoglobin, D-dimer, CRP, WBC, and male sex. The top five variables most associated  
3 with death were age, CRP, platelets, WBC, and D-Dimer. **Table S1** shows model  
4 coefficients and Harrell's C-statistic (survival concordance) from the simplified model  
5 using just these selected variables. **Table S2** shows similar results for the fully adjusted  
6 model. The simplified AKI Cox model had a survival C-statistic of 0.785 (95% CI, 0.769  
7 to 0.800), while the fully adjusted AKI Cox model had a C-statistic of 0.813 (95% CI,  
8 0.798 to 0.827). The simplified death Cox model had a survival C-statistic of 0.857 (95%  
9 CI, 0.841 to 0.874), while the fully adjusted death Cox model had a C-statistic of 0.878  
10 (95% CI, 0.863 to 0.892).

11 Cox model coefficients were used to predict AKI events within 3 days and death  
12 within 30 days of a new COVID-19 diagnosis (binary outcomes). **Table S1** and **Table**  
13 **S2** also displays AUC's for the simplified and fully adjusted coefficients respectively. For  
14 AKI in 3 days, using the simplified coefficients had an AUC of 0.787 (95% CI, 0.759 to  
15 0.814), using the fully adjusted coefficients had an AUC of 0.820 (95% CI, 0.794 to  
16 0.845), and the NRI was 0.041 (95% CI, 0.003 to 0.082). For death in 30 days, using  
17 the simplified coefficients had an AUC of 0.872 (95% CI, 0.854 to 0.890), the fully  
18 adjusted coefficients had an AUC of 0.893 (95% CI, 0.878 to 0.909), and the NRI was  
19 0.010 (95% CI, -0.007 to 0.029).

## 21 *Risk Score*



1  
2  
3 1 Model coefficients were rounded to obtain risk score component values for easier  
4  
5 2 clinical use. **Table 3** shows the risk score and internal validation results. For AKI in 3  
6  
7 3 days, the risk score had an AUC 0.785 (95% CI, 0.758, 0.813) and a cross validation  
8  
9 4 AUC of 0.776 (95% CI, 0.732, 0.816). For death in 30 days, the risk score had an AUC  
10  
11 5 of 0.861 (95% CI, 0.843 to 0.878) and a cross validation AUC of 0.860 (95% CI, 0.831,  
12  
13 6 0.886). **Figure 1A** plots ROC curves for using fully adjusted coefficients (from **Table S2**)  
14  
15 7 versus using risk scores (from **Table 3**) in predicting AKI in 3 days and death in 30  
16  
17 8 days.

18  
19  
20  
21  
22 9 Suggested risk stratification cutoffs were obtained. **Table S3** presents sensitivity,  
23  
24 10 specificity, and positive and negative likelihood ratios for all possible risk score cutoffs.  
25  
26 11 **Table 4** shows suggested risk stratification cutoffs and stratified observed and  
27  
28 12 estimated event rates. Higher risk scores had higher observed and estimated AKI and  
29  
30 13 death rates. **Figure 1B** plots Kaplan Meier event curves of AKI and death events by  
31  
32 14 simplified risk score categories. Event rates different by risk category for AKI ( $p<0.001$ )  
33  
34 15 and death ( $p<0.001$ ).

### 35 36 37 38 39 16 40 41 42 17 *Sensitivity Analysis*

43  
44  
45 18 We performed a competing risk regression analysis for AKI and death within 30  
46  
47 19 days. **Table S4** displays the multivariable cause-specific and subdistribution hazard  
48  
49 20 ratios for AKI events. Cause-specific and subdistribution hazard ratio estimates and  
50  
51 21 confidence intervals were nearly identical. We also performed a multiple imputation  
52  
53 22 analysis by imputing missing values for respiratory rate and IL-6 to evaluate their  
54  
55  
56  
57  
58  
59  
60

1 associations. **Table S5** shows that results were similar to non-imputation results, and  
2 increased respiratory rate and IL-6 were associated with increased hazards of AKI and  
3 death.

4 Of the 696 patients with an AKI event, 580 had a stage 1 AKI (83.3%), 29 had  
5 stage 2 (4.2%), and 87 had stage 3 (12.5%). Of the 117 patients with stage 2 or 3 AKI,  
6 there were 39 deaths (33.6%). In predicting stage 2 or 3 AKI as a single composite  
7 outcome among all 3,716 patients, the AKI risk score in **Table 3** had an AUC of 0.850  
8 (95% CI, 0.819 to 0.881). In predicting death among the 117 patients with stage 2 or 3  
9 AKI, the death risk score in **Table 3** had an AUC of 0.758 (95% CI, 0.671 to 0.846).

## 11 Discussion

12 In this retrospective study of over 3,700 adult patients without chronic kidney  
13 disease diagnosed with COVID-19 through May 2020 in the Boston area, we identified  
14 risk factors and biomarkers associated with AKI and death, and we developed and  
15 internally validated risk scores for predicting AKI and death. We found about one in five  
16 patients developed AKI and one in ten patients died. Increased age, male sex,  
17 increased white blood cells, C-reactive protein and D-Dimer and decreased hemoglobin  
18 and platelet levels were associated with AKI within 3 days and/or death within 30 days  
19 of a new COVID-19 diagnosis. A risk score using just these variables had similar  
20 internal accuracy as using all study variables. These results can assist in risk  
21 stratification of COVID-19 patients without CKD.

1 Many studies have found markedly increased COVID-19 fatality rates among  
2 older people. Studies from China, Spain, and Italy, and a meta-analysis of studies from  
3 34 different geographical locations have all found increased case or infection fatality  
4 rates among people >60 and >65 years old compared to younger populations.<sup>17–20</sup> We  
5 similarly observed older age had some of the strongest associations with death. Earlier  
6 studies have found various physiologic changes among elderly patients that may  
7 contribute to this age-related risk, such as decreased small airway clearance,  
8 decreased number of cilia and ciliated cells, and decreased upper airway size.<sup>21–23</sup>

9 Other studies have also reported worse COVID-19 outcomes among men. A  
10 study of over 3,300 patients in Montefiore Medical Center found male sex was  
11 associated with AKI in both COVID-19 positive and negative patients.<sup>8</sup> This study also  
12 provided a more complete discussion of other animal studies and meta-analyses to date  
13 that that have found associations between male sex and AKI in general. Studies of  
14 COVID-19 outcomes from March 2020 in Italy and the US also reported increased  
15 hospitalization and intensive care unit admission rates among male patients.<sup>24,25</sup> We  
16 similarly observed that AKI patients (60.3%) and patients that died (58.2%) were more  
17 likely to be male (overall 49.9%). However, after adjusting for other demographics,  
18 medical conditions, vital signs, and laboratory values, we found male sex was  
19 associated with AKI but not death.

20 Among laboratory values, C-reactive protein, hemoglobin, white blood cells, D-  
21 Dimer, and platelets were significantly associated with AKI and death and were included  
22 in risk scores. Although there has been debate about a standard definition for COVID-  
23 19 cytokine storm syndrome, patients with C-reactive protein may have excessive

1 immune activation, with C-reactive protein being produced by hepatocytes in response  
2 to IL-6 or ferritin.<sup>26</sup> Decreased hemoglobin may be reflective of kidney disease with  
3 decreased erythropoietin production or directly lead to decreased oxygenation of the  
4 kidneys. A study from Korea also found a higher risk of AKI in critically ill patients with a  
5 hemoglobin <10.5 g/dL.<sup>27</sup> Elevated white blood cell counts may suggest sepsis and be  
6 associated with life-threatening organ dysfunction.<sup>28</sup> Elevated D-Dimer levels may be  
7 indicative of a pro-thrombotic state, and a retrospective study from China found that D-  
8 Dimer >2000 ng/mL was associated with increased mortality.<sup>29</sup> However D-dimer levels  
9 have also been reported to be elevated at baseline in CKD patients,<sup>30</sup> so it is possible  
10 elevated D-Dimer may only be prognostic in non-CKD patients. Low platelets may also  
11 indicate a systemic coagulopathic process that places patients at an increased risk for  
12 death.<sup>28</sup>

13 The biomarker IL-6 was found to be a significant risk factor in regression  
14 analyses. However, a substantial proportion of patients in our study were missing IL-6  
15 values (78.3%), so IL-6 was not considered for risk score development. IL-6  
16 measurements were obtained at physician discretion and were likely reserved for  
17 severe cases. This may have also contributed to the missingness profile of IL-6.  
18 Previous studies have found IL-6 cutoffs of 80 and 86 IU/mL to have prognostic value  
19 for predicting respiratory failure and death respectively.<sup>31,32</sup>

20 We proposed risk scores for identifying AKI within 3 days and death within 30  
21 days of a new COVID-19 diagnosis along with suggested cutoffs. Although risk scores  
22 still need to be externally validated, being able to identify a few key biomarkers that are  
23 widely accessible can help focus chart reviews of new COVID-19 positive patients.

1 Varying score weights further highlight biomarkers to focus on, such as hemoglobin and  
2 male sex for AKI, age and platelets for death, and WBC, CRP, and D-Dimer for both.  
3 Larger scores directly correlate with worse outcomes and can help shape physician  
4 gestalt.

5 We explored death being a competing risk for AKI events as patients with death  
6 will not have any more creatinine measurements. Although an AKI does not exclude the  
7 possibility of death, competing risk analyses can still be performed investigating which  
8 event type occurs first.<sup>15</sup> The cause-specific hazards ratios (Cox hazard ratios) describe  
9 the rate of AKI events among those still alive and with no previous AKI events, while the  
10 subdistribution hazard ratios describes the overall rate of AKI events occurring before  
11 death. In our study both cause-specific and subdistribution hazard ratios were similar.  
12 Competing risk analyses were not performed for death events as having an AKI does  
13 not exclude death.

14 We also explored a subgroup of patients which developed stage 2 or 3 AKI. Our  
15 AKI risk score also performed well in identifying patients who developed stage 2 or 3  
16 AKI, suggesting higher risk scores also correlate with developing a higher stage AKI.  
17 Among patients who developed stage 2 or 3 AKI, the death risk score AUC had a larger  
18 confidence interval likely because of the smaller sample size and smaller number of  
19 death events.

20 Limitations to our study include the following. All results are associational and no  
21 causal effects should be interpreted. Vital and signs and laboratory values were those  
22 closest to COVID-19 diagnosis, and time-varying covariates were not incorporated into  
23 analyses. As the study was retrospective, selection bias cannot be excluded, and only

1 events within the MGB system were recorded. Our identified risk factors and risk scores  
2 are most applicable during a patient's initial COVID-19 positive test. Results may not be  
3 generalizable to more specific subgroups such as those requiring intensive care  
4 admission. Patients in the Boston area may not be reflective of those in other healthcare  
5 systems, and the study population included only COVID-19 positive patients without  
6 CKD. The study population included patients in the first wave of COVID-19, and results  
7 should be cautiously applied to subsequent waves of COVID-19 due to differences in  
8 COVID-19 variants and treatment protocols. Future work may further stratify AKI events  
9 by stage and time of acquisition (relative to hospital admission), investigate outpatient,  
10 hospitalized, and critically ill patients separately, focus on CKD patients, validate results  
11 on a separate cohort, and explore hospital specific effects.

12 We investigated AKI and death outcomes among adult COVID-19 patients  
13 without CKD in the Boston area. We identified risk factors and developed and evaluated  
14 risk assessment tools for identifying COVID-19 patients developing AKI and death.  
15 Hemoglobin, D-Dimer, CRP, WBC, and male sex were the strongest predictive  
16 biomarkers for AKI. Age, CRP, platelets, WBC, and D-Dimer were most predictive for  
17 death. Our study significantly contributes to epidemiological knowledge of COVID-19  
18 outcomes and introduces simple tools to assist with rapid risk assessment.

## 19 **Acknowledgements**

20 **Contributors:** None

21 **Funding statement:** This work was supported by the National Institutes of Health grant  
22 number T32-GM135117 (DL).

23 **Competing interests:** The authors declare no relevant competing interests.

1  
2  
3 1 **Authors' contributions:** DL and HR drafted the manuscript. HR, PX, DW obtained the  
4 2 data. DL performed the analyses. DL, HR, DJV, PS, QL, and XL contributed to the  
5 3 design of the study. All authors were involved with interpretation of the data and critical  
6 4 revision and final approval of the article.  
7

8  
9 5 **Availability of data and materials:** Patient data is not available, but requests for  
10 6 surrogate data may be made to the corresponding authors. However, code for all  
11 7 analyses will be available at <https://github.com/lin-lab>.  
12

13 8 **Patient and public involvement:** Patients and the public were not involved in the  
14 9 planning of this project.  
15

16 10 **Research ethics approval human subjects:** The Mass General Brigham Institutional  
17 11 Review Board approved this study, and the approval number was 2020P001661. Only  
18 12 deidentified patient electronic health record data were used.  
19  
20 13

## References

1. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. 2020;98(1):219-227. doi:10.1016/j.kint.2020.04.003
2. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. *JASN*. 2020;31(8):1683-1687. doi:10.1681/ASN.2020040432
3. Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol*. Published online October 15, 2020. doi:10.1038/s41581-020-00356-5
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
5. Guan W jie, Ni Z yi, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
6. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. Remuzzi G, ed. *PLoS Med*. 2020;17(10):e1003406. doi:10.1371/journal.pmed.1003406
7. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney International*. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
8. Fisher M, Neugarten J, Bellin E, et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. *JASN*. 2020;31(9):2145-2157. doi:10.1681/ASN.2020040509
9. Zahid U, Ramachandran P, Spitalewitz S, et al. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications. *Am J Nephrol*. 2020;51(10):786-796. doi:10.1159/000511160
10. Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. *JASN*. 2021;32(1):151-160. doi:10.1681/ASN.2020050615
11. Smilowitz NR, Nguy V, Aphinyanaphongs Y, et al. Multiple Biomarker Approach to Risk Stratification in COVID-19. *Circulation*. Published online February 15, 2021:CIRCULATIONAHA.120.053311. doi:10.1161/CIRCULATIONAHA.120.053311



12. *KDIGO Clinical Practice Guideline for Acute Kidney Injury*. Kidney Disease Improving Global Outcomes; 2012:1-141. Accessed January 8, 2021. <https://linkinghub.elsevier.com/retrieve/pii/S2157171615310388>
13. Hu FC. My.stepwise.coxph, Stepwise Variable Selection Procedure For Cox's Proportional Hazards Model And Cox's Model. R Documentation. Accessed February 23, 2021. <https://www.rdocumentation.org/packages/My.stepwise/versions/0.1.0/topics/My.stepwise.coxph>
14. McGee S. Simplifying likelihood ratios. *J Gen Intern Med*. 2002;17(8):647-650. doi:10.1046/j.1525-1497.2002.10750.x
15. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719
16. Rubin DB. Inference and Missing Data. *Biometrika*. 1976;63(3):581-592.
17. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious Diseases*. 2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7
18. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ*. Published online November 27, 2020:m4509. doi:10.1136/bmj.m4509
19. Signorelli C, Odone A. Age-specific COVID-19 case-fatality rate: no evidence of changes over time. *Int J Public Health*. 2020;65(8):1435-1436. doi:10.1007/s00038-020-01486-0
20. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol*. 2020;35(12):1123-1138. doi:10.1007/s10654-020-00698-1
21. Martin SE, Mathur R, Marshall I, Douglas NJ. The effect of age, sex, obesity and posture on upper airway size. *European Respiratory Journal*. 1997;10(9):2087-2090. doi:10.1183/09031936.97.10092087
22. Svartengren M. Long-term clearance from small airways decreases with age. *European Respiratory Journal*. 2005;26(4):609-615. doi:10.1183/09031936.05.00002105
23. Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. *Aging Clin Exp Res*. 2020;32(8):1599-1608. doi:10.1007/s40520-020-01631-y

- 1  
2  
3 1 24. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of  
4 2 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy  
5 3 Region, Italy. *JAMA*. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394  
6  
7  
8 4 25. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of  
9 5 Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 —  
10 6 COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep*.  
11 7 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3  
12  
13 8 26. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the  
14 9 controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur Respir*  
15 10 *J*. 2020;56(4). doi:10.1183/13993003.03006-2020  
16  
17  
18 11 27. Han SS, Baek SH, Ahn SY, et al. Anemia Is a Risk Factor for Acute Kidney Injury  
19 12 and Long-Term Mortality in Critically Ill Patients. *Tohoku J Exp Med*.  
20 13 2015;237(4):287-295. doi:10.1620/tjem.237.287  
21  
22 14 28. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,  
23 15 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-  
24 16 19): A Review. *JAMA*. 2020;324(8):782. doi:10.1001/jama.2020.12839  
25  
26  
27 17 29. Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and  
28 18 mortality in COVID-19 patients: a case control study. *J Intensive Care*. 2020;8.  
29 19 doi:10.1186/s40560-020-00466-z  
30  
31 20 30. Lindner G, Funk GC, Pfortmueller CA, et al. D-dimer to Rule Out Pulmonary  
32 21 Embolism in Renal Insufficiency. *The American Journal of Medicine*.  
33 22 2014;127(4):343-347. doi:10.1016/j.amjmed.2013.12.003  
34  
35  
36 23 31. Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the  
37 24 need for mechanical ventilation in COVID-19. *Journal of Allergy and Clinical*  
38 25 *Immunology*. 2020;146(1):128-136. doi:10.1016/j.jaci.2020.05.008  
39  
40 26 32. Laguna-Goya R, Utrero-Rico A, Talayero P, et al. IL-6–based mortality risk model  
41 27 for hospitalized patients with COVID-19. *Journal of Allergy and Clinical*  
42 28 *Immunology*. 2020;146(4):799-807.e9. doi:10.1016/j.jaci.2020.07.009  
43  
44  
45  
46  
47  
48 30  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Figure Legends**

4 **2 Fig. 1 Receiver Operating Characteristics and Kaplan Meier Event Curves Using**  
5 **3 Selected Variables.**

6 **4 (A)** Receiver operating characteristic (ROC) curves for acute kidney injury (AKI) within 3  
7 days and death within 30 days using fully adjusted model coefficients and developed  
8 risk score. Each line represents a different model's predictions with the given variables.  
9 HGB = Hemoglobin, CRP = C-reactive protein, WBC = white blood cell, PLT = Platelets.

10 **8 (B)** Kaplan-Meier event curves for AKI events and death events stratified by AKI and  
11 death scores. Time begins at positive COVID-19 test.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 **Table 1.** Characteristics of Patients with Acute Kidney Injury, Patients that Died, and All  
 2 Patients.

Variable, n (%)	AKI (n=696)	Died (n=347)	Total (n=3,716)
Age (years)			
<45	86 (12.4)	7 (2.0)	980 (26.4)
45-65	245 (35.2)	55 (15.9)	1,310 (35.3)
>65	365 (52.4)	285 (82.1)	1,426 (38.4)
Sex (Male)	420 (60.3)	202 (58.2)	1,855 (49.9)
Race			
White	407 (58.5)	242 (69.7)	2,091 (56.3)
Black	110 (15.8)	50 (14.4)	568 (15.3)
Hispanic	22 (3.2)	9 (2.6)	135 (3.6)
Asian	27 (3.9)	8 (2.3)	140 (3.8)
Other	130 (18.7)	38 (11.0)	782 (21.0)
Diabetes	197 (28.3)	87 (25.1)	727 (19.6)
Cardiovascular Disease	67 (9.6)	49 (14.1)	231 (6.2)
Hypertension	135 (19.4)	65 (18.7)	484 (13.0)
Heart Failure	39 (5.6)	38 (11.0)	134 (3.6)
Medical Conditions (number)			
0	397 (57.0)	189 (54.5)	2,565 (69.0)
1	190 (27.3)	95 (27.4)	811 (21.8)
2	83 (11.9)	47 (13.5)	264 (7.1)
3+	26 (3.7)	16 (4.6)	76 (2.0)
Body Mass Index (kg/m <sup>2</sup> )			
<25	165 (23.7)	115 (33.1)	833 (22.4)
25-30	229 (32.9)	110 (31.7)	1,334 (35.9)
>30	302 (43.4)	122 (35.2)	1,549 (41.7)
Temperature (F)			
97-100.4	423 (60.8)	201 (57.9)	2,745 (73.9)
<97	35 (5.0)	22 (6.3)	190 (5.1)
>100.4	238 (34.2)	124 (35.7)	781 (21.0)
Heart Rate (beats/min)			
60-110	576 (82.8)	274 (79.0)	3,194 (86.0)
<60	61 (8.8)	30 (8.6)	275 (7.4)
>110	59 (8.5)	43 (12.4)	247 (6.6)
Systolic Blood Pressure (mmHg)			
90-180	635 (91.2)	305 (87.9)	3,549 (95.5)
<90	48 (6.9)	35 (10.1)	117 (3.1)
>180	13 (1.9)	7 (2.0)	50 (1.3)
Respiratory Rate (per minute)			

<20	245 (35.2)	92 (26.5)	1,692 (45.5)
>20	364 (52.3)	202 (58.2)	1,237 (33.3)
NA (Missing)	87 (12.5)	53 (15.3)	787 (21.2)
White Blood Cell (thousand cells/mm <sup>3</sup> )			
3.5-11	428 (61.5)	189 (54.5)	2,942 (79.2)
<3.5	39 (5.6)	26 (7.5)	267 (7.2)
>11	229 (32.9)	132 (38.0)	507 (13.6)
Hemoglobin (g/dL)			
12+	201 (28.9)	138 (39.8)	2,250 (60.5)
10-12	204 (29.3)	88 (25.4)	883 (23.8)
<10	291 (41.8)	121 (34.9)	583 (15.7)
Platelets (per $\mu$ L)			
>100	643 (92.4)	310 (89.3)	3,600 (96.9)
<100	53 (7.6)	37 (10.7)	116 (3.1)
C-Reactive Protein (mg/L)			
<50	197 (28.3)	62 (17.9)	1,706 (45.9)
50-100	149 (21.4)	63 (18.2)	1,011 (27.2)
>100	350 (50.3)	222 (64.0)	999 (26.9)
Ferritin ( $\mu$ g/L)			
<250	105 (15.1)	52 (15.0)	950 (25.6)
250-1000	327 (47.0)	155 (44.7)	1,894 (51.0)
>1000	264 (37.9)	140 (40.3)	872 (23.5)
D-Dimer (ng/mL)			
<1000	136 (19.5)	60 (17.3)	1,726 (46.4)
1000-2000	217 (31.2)	101 (29.1)	1,076 (29.0)
>2000	343 (49.3)	186 (53.6)	914 (24.6)
Interleukin-6 (IU/mL)			
<40	121 (17.4)	26 (7.5)	438 (11.8)
40-80	68 (9.8)	33 (9.5)	137 (3.7)
>80	136 (19.5)	58 (16.7)	196 (5.3)
NA (Missing)	371 (53.3)	230 (66.3)	2,945 (79.3)

AKI = acute kidney injury

1 **Table 2.** Multivariable Cox Regression Results.

Variable	AKI	Death
Age (years)		
<45	Reference	Reference
45-65	<b>1.71 (1.33, 2.21)</b>	<b>5.33 (2.42, 11.8)</b>
>65	<b>2.16 (1.66, 2.80)</b>	<b>23.4 (10.9, 50.1)</b>
Sex (Male)	<b>1.51 (1.28, 1.77)</b>	1.16 (0.92, 1.45)
Race		
White	Reference	Reference
Black	0.89 (0.72, 1.11)	<b>0.66 (0.48, 0.92)</b>
Hispanic	0.89 (0.58, 1.38)	0.62 (0.32, 1.23)
Asian	0.96 (0.65, 1.43)	<b>0.46 (0.22, 0.93)</b>
Other	1.11 (0.90, 1.37)	0.72 (0.50, 1.02)
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.28 (1.07, 1.53)</b>	<b>1.07 (0.83, 1.38)</b>
2	<b>1.67 (1.30, 2.13)</b>	<b>1.40 (1.01, 1.95)</b>
3+	<b>1.82 (1.21, 2.75)</b>	<b>1.61 (0.95, 2.73)</b>
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.09 (0.89, 1.33)	0.78 (0.59, 1.02)
>30	<b>1.42 (1.17, 1.74)</b>	0.94 (0.72, 1.22)
Temperature (F)		
97-100.4	Reference	Reference
<97	1.07 (0.75, 1.51)	1.18 (0.75, 1.85)
>100.4	<b>1.59 (1.34, 1.88)</b>	<b>1.54 (1.22, 1.96)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.24 (0.95, 1.63)	0.97 (0.66, 1.43)
>110	1.11 (0.85, 1.47)	<b>1.78 (1.28, 2.48)</b>
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.90 (1.41, 2.57)</b>	<b>2.10 (1.45, 3.04)</b>
>180	0.96 (0.55, 1.67)	0.90 (0.42, 1.92)
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.78 (0.55, 1.09)	1.10 (0.72, 1.68)
>11	<b>1.77 (1.49, 2.12)</b>	<b>2.32 (1.82, 2.95)</b>
Hemoglobin (g/dL)		
>12	Reference	Reference
10-12	<b>2.15 (1.75, 2.64)</b>	0.88 (0.67, 1.16)
<10	<b>3.72 (3.03, 4.57)</b>	1.03 (0.78, 1.35)

Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.74 (1.30, 2.34)</b>	<b>2.60 (1.79, 3.77)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.96 (0.77, 1.20)	<b>1.46 (1.02, 2.10)</b>
>100	<b>1.57 (1.29, 1.91)</b>	<b>3.61 (2.65, 4.93)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	<b>1.29 (1.03, 1.63)</b>	0.91 (0.65, 1.26)
>1000	<b>1.69 (1.31, 2.17)</b>	1.14 (0.80, 1.62)
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.67 (1.33, 2.09)</b>	1.21 (0.87, 1.69)
>2000	<b>2.11 (1.68, 2.65)</b>	<b>1.82 (1.31, 2.52)</b>

1

1 **Table 3.** Risk Score and Internal Validation Results.

AKI in 3 days (max 6)		Death in 30 days (max 7)	
Risk Score			
Variable	Value	Variable	Value
Hemoglobin <10 g/dL	2	Age > 65 years	3
Hemoglobin 10-12 g/dL	1	Age 45-65 years	2
D-Dimer > 1,000 ng/mL	1	CRP > 100 mg/L	1
CRP > 100 mg/L	1	Platelets < 100 per $\mu$ L	1
WBC > 11,000 cells/mm <sup>3</sup>	1	WBC > 11,000 cells/mm <sup>3</sup>	1
Male Sex	1	D-Dimer > 2,000 ng/mL	1
Internal Validation			
Validation Type	AUC (95% intervals)	Validation Type	AUC (95% intervals)
Whole Data	0.785 (0.758, 0.813)	Whole Data	0.861 (0.843, 0.878)
Cross Validation	0.776 (0.732, 0.816)	Cross Validation	0.860 (0.831, 0.886)

2 CRP = C-reactive protein, WBC = white blood cells.

3 Whole data validation presents area under the curve (AUC) estimates and 95%  
4 confidence intervals.

5 Internal cross validation presents mean AUC and 95% central interval (2.5<sup>th</sup> and 97.5<sup>th</sup>  
6 percentiles).

7




1 **Table 4.** Suggested Risk Stratification Cutoffs and Observed and Estimated Event  
 2 Rates.

<b>AKI Risk Score</b>				
<b>Risk Level</b>	<b>Total Score</b>	<b>Observed Total AKI (%)</b>	<b>Estimated 3 Day AKI (%)</b>	<b>Estimated 30 Day AKI (%)</b>
Low Risk	0-1	5.2	1.7	5.4
Moderate Risk	2-3	18.4	6.2	19.7
High Risk	4-6	54.7	21.6	59.7
<b>Death Risk Score</b>				
<b>Risk Level</b>	<b>Total Score</b>	<b>Observed Total Death (%)</b>	<b>Estimated 30 Day Death (%)</b>	<b>Estimated 60 Day Death (%)</b>
Low Risk	0-3	1.7	1.6	2.0
Moderate Risk	4	10.4	10.2	12.3
High Risk	5-7	37.9	37.3	43.4

3 Observed percentages are from the observed data

4 Estimated percentages are from Kaplan-Meier event curves

5



(A) Receiver operating characteristic (ROC) curves for acute kidney injury (AKI) within 3 days and death within 30 days using fully adjusted model coefficients and developed risk score. Each line represents a different model's predictions with the given variables. HGB = Hemoglobin, CRP = C-reactive protein, WBC = white blood cell, PLT = Platelets.

(B) Kaplan-Meier event curves for AKI events and death events stratified by AKI and death scores. Time begins at positive COVID-19 test.

450x448mm (96 x 96 DPI)

## Supplemental Methods – Additional Details

### *Statistical Analyses*

Descriptive statistics and receiver operating characteristics (ROC) were calculated using R base functions. Cox proportional hazards models were fit using the “survival” package. Inspection of AKI and death Kaplan-Meier event curves stratified by each variable revealed no obvious violations of the proportional hazards assumption.

The variable selection procedure was implemented using the “My.stepwise” package. In addition to the variables included in fully adjusted Cox proportional hazards models, age >45 years, medical conditions >1, medical conditions >2, BMI > 25 kg/m<sup>2</sup>, hemoglobin <12 g/dL, CRP > 500 mg/L, ferritin >250 µg/L, and D-Dimer > 1,000 ng/mL were also included. The package “glmnet” was used to reformat data so that the variable selection procedure could be applied. The selection procedure alternates between “forward” steps of adding variables and “backwards” steps of removing variables. The significance level for entry and for staying was conservatively set at 0.15 as suggested by function details. The top 5 variables (top 6 dummy variables) were included in risk scores. Simplified risk score values were obtained by rounding model coefficients to the nearest integer.

ROC curves were created using “plotROC” and AUC values and confidence intervals were obtained from “pROC”. Event curves were created using “survminer” and “mstate”. Harrell’s C-statistics were obtained from Cox proportional hazards model output, and net reclassification of improvement was obtained from “nricens”.

1  
2  
3 Competing risk analyses used the “cmprsk” package, and multiple imputation  
4 analyses used the “mice” package. The packages “ggplot2”, “dplyr”, “plyr”, “ggfortify”,  
5  
6 and “cowplot” were used to process results and create figures. Code for replicating all  
7  
8 analyses will be available online.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table S1.** Coefficients from simplified Cox regression models to calculated and internal validation statistics using these coefficient linear predictions.

AKI		Death	
Simplified Model Coefficients			
Variable	Coefficient Value	Variable	Coefficient Value
Hemoglobin <10 g/dL	1.50	Age > 65 years	3.19
Hemoglobin 10-12 g/dL	0.85	Age 45-65 years	1.65
D-Dimer > 1,000 ng/mL	0.76	CRP > 100 mg/L	1.21
CRP > 100 mg/L	0.64	Platelets < 100 per $\mu$ L	1.20
WBC > 11,000 cells/mm <sup>3</sup>	0.59	WBC > 11,000 cells/mm <sup>3</sup>	0.87
Male Sex	0.54	D-Dimer > 2,000 ng/mL	0.58
Internal Validation			
Statistic	Estimate (95% CI)	Statistic	Estimate (95% CI)
Harrell's Survival C-Statistic (Concordance)	0.785 (0.769, 0.800)	Harrell's Survival C-Statistic (Concordance)	0.857 (0.841, 0.874)
AKI in 3 Days AUC	0.787 (0.759, 0.814)	Death in 30 Days AUC	0.872 (0.854, 0.890)

AKI = acute kidney injury, CRP = C-reactive protein, WBC = white blood cells, AUC = area under the curve, CI = confidence interval

**Table S2.** Coefficients from fully adjusted Cox regression models and internal validation statistics using these coefficient linear predictions.

AKI		Death	
Fully Adjusted Model Coefficients			
Variable	Coefficient Value	Variable	Coefficient Value
Age 45-65 years	0.54	Age 45-65 years	1.67
Age > 65 years	0.77	Age > 65 years	3.15
Male Sex	0.41	Male Sex	0.14
Race Black	-0.12	Race Black	-0.41
Race Hispanic	-0.12	Race Hispanic	-0.47
Race Asian	-0.04	Race Asian	-0.79
Race Other	0.11	Race Other	-0.33
Medical Conditions 1	0.25	Medical Conditions 1	0.07
Medical Conditions 2	0.51	Medical Conditions 2	0.34
Medical Conditions 3+	0.60	Medical Conditions 3+	0.48
BMI 25-30 kg/m <sup>2</sup>	0.08	BMI 25-30 kg/m <sup>2</sup>	-0.25
BMI >30 kg/m <sup>2</sup>	0.35	BMI >30 kg/m <sup>2</sup>	-0.06
Temp < 97 F	0.06	Temp < 97 F	0.16
Temp > 100.4 F	0.46	Temp > 100.4 F	0.43
Heart rate < 60 beats/min	0.22	Heart rate < 60 beats/min	-0.03
Heart rate < 110 beats/min	0.11	Heart rate < 110 beats/min	0.58
SBP < 90 mmHg	0.64	SBP < 90 mmHg	0.74
SBP > 180 mmHg	-0.04	SBP > 180 mmHg	-0.11
WBC < 3,500 cells/mm <sup>3</sup>	-0.25	WBC < 3,500 cells/mm <sup>3</sup>	0.09
WBC > 11,000 cells/mm <sup>3</sup>	0.57	WBC > 11,000 cells/mm <sup>3</sup>	0.84
Hemoglobin <10 g/dL	0.77	Hemoglobin <10 g/dL	-0.13
Hemoglobin 10-12 g/dL	1.31	Hemoglobin 10-12 g/dL	0.03
Platelets < 100 per $\mu$ L	0.56	Platelets < 100 per $\mu$ L	0.96
CRP 50-100 mg/L	-0.04	CRP 50-100 mg/L	0.38
CRP > 100 mg/L	0.45	CRP > 100 mg/L	1.28
Ferritin 250-1000 $\mu$ g/L	0.26	Ferritin 250-1000 $\mu$ g/L	-0.10
Ferritin >1000 $\mu$ g/L	0.52	Ferritin >1000 $\mu$ g/L	0.13
D-Dimer 1,000-2,000 ng/mL	0.51	D-Dimer 1,000-2,000 ng/mL	0.19
D-Dimer > 2,000 ng/mL	0.75	D-Dimer > 2,000 ng/mL	0.60
Internal Validation			

<b>Statistic</b>	<b>Estimate (95% CI)</b>	<b>Statistic</b>	<b>Estimate (95% CI)</b>
Harrell's Survival C-Statistic (Concordance)	0.813 (0.798, 0.827)	Harrell's Survival C-Statistic (Concordance)	0.878 (0.863, 0.892)
AKI in 3 Days AUC	0.820 (0.794, 0.845)	Death in 30 Days AUC	0.893 (0.878, 0.909)

For peer review only

**Table S3.** Sensitivity, specificity, and likelihood ratios (LR) for positive and negative results of risk scores predicting acute kidney injury (AKI) within 3 days and death within 30 days of a positive COVID-19 test.

Cutoff	Sensitivity	Specificity	Positive LR	Negative LR
<b>Simplified AKI Risk Score (max 6)</b>				
<b>Rule in</b>				
0	1.000	0.000	1.000	NA
1	0.992	0.154	1.170	0.050
2	0.892	0.455	1.640	0.240
3	0.759	0.713	2.640	0.340
4	0.526	0.860	3.750	0.550
5	0.257	0.946	4.770	0.790
6	0.068	0.989	6.400	0.940
7	0.000	1.000	NA	1.000
<b>Simplified Death Risk Score (max 7)</b>				
0	1.000	0.000	1.000	NA
1	1.000	0.156	1.190	0.000
2	0.994	0.233	1.300	0.030
3	0.984	0.433	1.740	0.040
4	0.891	0.665	2.660	0.160
5	0.637	0.890	5.760	0.410
6	0.224	0.978	10.400	0.790
7	0.019	1.000	Inf	0.980
8	0.000	1.000	NA	1.000

Cutoff denotes treating a score greater than or equal a cutoff value as a positive.

Positive likelihood ratio (LR) is sensitivity / (1-specificity)

Negative likelihood ratio (LR) is (1-sensitivity) / specificity

Sensitivity 1 specificity 0 indicates all individuals identified as positive

Sensitivity 0 specificity 1 indicates all individuals identified as negative

Approximate probability changes can be obtained by  $\approx 0.18 * \ln(\text{LR})$  (McGee 2002)



**Table S4.** Multivariable AKI cause-specific hazard (AKI event, death censor) and AKI subdistribution hazard (AKI and death competing risks) model results.

Variable	Cause-Specific	Subdistribution
Age (years)		
<45	Reference	Reference
45-65	<b>1.71 (1.33, 2.21)</b>	<b>1.67 (1.31, 2.14)</b>
>65	<b>2.16 (1.66, 2.80)</b>	<b>1.92 (1.48, 2.50)</b>
Sex (Male)	<b>1.51 (1.28, 1.77)</b>	<b>1.53 (1.29, 1.81)</b>
Race		
White	Reference	Reference
Black	0.89 (0.72, 1.11)	0.91 (0.73, 1.14)
Hispanic	0.89 (0.58, 1.38)	0.96 (0.65, 1.41)
Asian	0.96 (0.65, 1.43)	0.97 (0.67, 1.41)
Other	1.11 (0.90, 1.37)	1.13 (0.91, 1.40)
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.28 (1.07, 1.53)</b>	<b>1.27 (1.06, 1.53)</b>
2	<b>1.67 (1.30, 2.13)</b>	<b>1.66 (1.29, 2.12)</b>
3+	<b>1.82 (1.21, 2.75)</b>	<b>1.81 (1.18, 2.77)</b>
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.09 (0.89, 1.33)	1.11 (0.90, 1.38)
>30	<b>1.42 (1.17, 1.74)</b>	<b>1.47 (1.19, 1.81)</b>
Temperature (F)		
97-100.4	Reference	Reference
<97	1.07 (0.75, 1.51)	1.03 (0.71, 1.48)
>100.4	<b>1.59 (1.34, 1.88)</b>	<b>1.62 (1.37, 1.91)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.24 (0.95, 1.63)	1.30 (0.98, 1.72)
>110	1.11 (0.85, 1.47)	1.04 (0.78, 1.38)
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.90 (1.41, 2.57)</b>	<b>1.73 (1.28, 2.35)</b>
>180	0.96 (0.55, 1.67)	1.00 (0.55, 1.84)
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.78 (0.55, 1.09)	0.79 (0.56, 1.12)
>11	<b>1.77 (1.49, 2.12)</b>	<b>1.68 (1.39, 2.04)</b>
Hemoglobin (g/dL)		
>12	Reference	Reference
10-12	<b>2.15 (1.75, 2.64)</b>	<b>2.27 (1.83, 2.81)</b>

<10	<b>3.72 (3.03, 4.57)</b>	<b>3.94 (3.17, 4.90)</b>
Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.74 (1.30, 2.34)</b>	<b>1.63 (1.19, 2.24)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.96 (0.77, 1.20)	0.94 (0.76, 1.18)
>100	<b>1.57 (1.29, 1.91)</b>	<b>1.48 (1.20, 1.82)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	<b>1.29 (1.03, 1.63)</b>	<b>1.33 (1.05, 1.69)</b>
>1000	<b>1.69 (1.31, 2.17)</b>	<b>1.70 (1.31, 2.21)</b>
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.67 (1.33, 2.09)</b>	<b>1.70 (1.36, 2.13)</b>
>2000	<b>2.11 (1.68, 2.65)</b>	<b>2.07 (1.63, 2.63)</b>

**Table S5.** Multiple Imputation Multivariable Cox Regression Results.

Variable	AKI	Death
Age (years)		
<45	Reference	Reference
45-65	<b>1.58 (1.22, 2.04)</b>	<b>4.60 (2.07, 10.3)</b>
>65	<b>1.86 (1.43, 2.43)</b>	<b>18.3 (8.47, 39.6)</b>
Sex (Male)	<b>1.42 (1.20, 1.68)</b>	1.05 (0.83, 1.33)
Race		
White	Reference	Reference
Black	0.87 (0.69, 1.08)	<b>0.65 (0.47, 0.89)</b>
Hispanic	0.97 (0.63, 1.50)	0.66 (0.33, 1.32)
Asian	0.92 (0.61, 1.38)	<b>0.39 (0.19, 0.80)</b>
Other	1.05 (0.85, 1.30)	<b>0.67 (0.47, 0.96)</b>
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.32 (1.10, 1.58)</b>	1.07 (0.82, 1.39)
2	<b>1.62 (1.25, 2.09)</b>	1.33 (0.94, 1.89)
3+	<b>1.88 (1.24, 2.87)</b>	1.62 (0.94, 2.79)
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.10 (0.90, 1.36)	0.81 (0.61, 1.07)
>30	<b>1.33 (1.09, 1.63)</b>	0.86 (0.65, 1.13)
Temperature (F)		
97-100.4	Reference	Reference
<97	0.95 (0.66, 1.36)	1.11 (0.69, 1.77)
>100.4	<b>1.40 (1.18, 1.66)</b>	<b>1.40 (1.09, 1.81)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.13 (0.86, 1.48)	0.86 (0.58, 1.30)
>110	0.98 (0.74, 1.31)	1.41 (0.95, 2.08)
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.74 (1.28, 2.37)</b>	<b>1.76 (1.19, 2.60)</b>
>180	1.22 (0.68, 2.19)	1.16 (0.52, 2.55)
Respiratory Rate (per minute)		
<20	Reference	Reference
>20	<b>1.72 (1.45, 2.03)</b>	<b>1.98 (1.53, 2.55)</b>
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.81 (0.58, 1.15)	1.25 (0.81, 1.95)
>11	<b>1.61 (1.34, 1.93)</b>	<b>1.95 (1.52, 2.51)</b>
Hemoglobin (g/dL)		

>12	Reference	Reference
10-12	<b>2.02 (1.64, 2.49)</b>	0.81 (0.60, 1.09)
<10	<b>3.31 (2.68, 4.08)</b>	0.86 (0.65, 1.14)
Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.85 (1.37, 2.49)</b>	<b>2.51 (1.72, 3.68)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.99 (0.79, 1.24)	<b>1.60 (1.10, 2.33)</b>
>100	<b>1.47 (1.20, 1.80)</b>	<b>3.18 (2.32, 4.37)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	1.18 (0.93, 1.50)	0.77 (0.54, 1.12)
>1000	<b>1.48 (1.14, 1.91)</b>	0.89 (0.60, 1.32)
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.59 (1.27, 2.00)</b>	1.16 (0.82, 1.63)
>2000	<b>2.03 (1.60, 2.57)</b>	<b>1.73 (1.23, 2.44)</b>
Interleukin-6 (IU/mL)		
<40	Reference	Reference
40-80	<b>1.39 (1.03, 1.86)</b>	<b>2.75 (1.80, 4.21)</b>
>80	<b>1.91 (1.50, 2.43)</b>	<b>3.07 (2.01, 4.69)</b>

Pooled hazard ratios calculated using 10 different imputation datasets with imputed values for missing respiratory rate and IL-6.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7-8 7-8 7-8 7-8 7-8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9

1 2 3 4 5 6 7 8	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10
9 10 11	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
12	<b>Discussion</b>			
13 14	Key results	18	Summarise key results with reference to study objectives	12-14
15 16	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
17 18 19	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
20 21	Generalisability	21	Discuss the generalisability (external validity) of the study results	15
22	<b>Other information</b>			
23 24 25	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

## Risk Assessment for Acute Kidney Injury and Death among New COVID-19 Positive Adult Patients without Chronic Kidney Disease: Retrospective Cohort Study among 3 US Hospitals

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053635.R2
Article Type:	Original research
Date Submitted by the Author:	01-Dec-2021
Complete List of Authors:	Li, Daniel; Harvard University T H Chan School of Public Health; Johns Hopkins School of Medicine Ren, Hui; Harvard Medical School, Department of Radiology Varelmann, Dirk J.; Brigham and Women's Hospital, Department of Anesthesiology Sarin, Pankaj; Brigham and Women's Hospital, Department of Anesthesiology Xu, Pengcheng; Harvard Medical School, Department of Radiology Wu, Dufan; Harvard Medical School, Department of Radiology Li, Quanzheng; Harvard Medical School, Department of Radiology Lin, Xihong; Harvard University T H Chan School of Public Health, Department of Biostatistics; Harvard University, Department of Statistics
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Research methods, Health informatics
Keywords:	COVID-19, EPIDEMIOLOGY, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3 1 **Title Page**  
4  
5 2

6 3 **Risk Assessment for Acute Kidney Injury and Death among New COVID-19**  
7 4 **Positive Adult Patients without Chronic Kidney Disease: Retrospective Cohort**  
8 5 **Study among 3 US Hospitals**  
9 6

10 7 *Short Title:* AKI and Death among COVID-19 Patients without CKD  
11 8

12 9 Daniel Li, MD, MA,<sup>1,2\*</sup> Hui Ren, MD, PhD, MPH<sup>3\*</sup> Dirk J. Varelmann, MD,<sup>4</sup> Pankaj Sarin,  
13 10 MD,<sup>4</sup> Pengcheng Xu, BS,<sup>3</sup> Dufan Wu, PhD,<sup>3</sup> Quanzheng Li, PhD,<sup>3\*\*</sup> Xihong Lin,  
14 11 PhD<sup>1,5,6\*\*</sup>  
15  
16  
17

18 12 \*Contributed equally, co-first authorship  
19

20 13 <sup>1</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston MA.  
21

22 14 <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore MD.  
23

24 15 <sup>3</sup>Department of Radiology, Massachusetts General Hospital and Harvard Medical  
25 16 School, Boston MA.

26 17 <sup>4</sup>Department of Anesthesiology, Brigham and Women's Hospital, Boston MA.  
27

28 18 <sup>5</sup>Department of Statistics, Harvard University, Cambridge MA.  
29

30 19 <sup>6</sup>Broad Institute of MIT and Harvard, Cambridge, MA.  
31  
32

33 21 **\*\*Correspondence:** Xihong Lin, Quanzheng Li  
34

35 22 Department of Biostatistics  
36

37 23 655 Huntington Ave  
38

39 24 Building II, Room 419  
40

41 25 Boston, MA 02115  
42

43 26 Telephone: 617 432 2914  
44

45 27 Fax: 617 432 5619  
46

47 28 **Email:** [xlin@hsph.harvard.edu](mailto:xlin@hsph.harvard.edu), [li.quanzheng@mgh.harvard.edu](mailto:li.quanzheng@mgh.harvard.edu)  
48  
49

50 30 Abstract 277 words; Main Text 3,138 words; References 32; Tables 4; Figures 1;  
51

52 31 Appendix Tables 5  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Abstract

2 **Objective:** To develop simple but clinically informative risk stratification tools using a  
3 few top demographic factors and biomarkers at COVID-19 diagnosis to predict acute  
4 kidney injury (AKI) and death.

5 **Design:** Retrospective cohort analysis, follow-up from February 1 through May 28,  
6 2020.

7 **Setting:** 3 teaching hospitals, 2 urban and 1 community-based in the Boston area.

8 **Participants:** Eligible patients were at least 18 years old, tested COVID-19 positive  
9 from February 1 through May 28, 2020, and had at least two serum creatinine  
10 measurements within 30 days of a new COVID-19 diagnosis. Exclusion criteria were  
11 having CKD or having a previous AKI within 3 months of a new COVID-19 diagnosis.

12 **Main Outcomes and Measures:** Time from new COVID-19 diagnosis until AKI event,  
13 time until death event.

14 **Results:** Among 3,716 patients, there were 1,855 (49.9%) males and the average age  
15 was 58.6 years (SD 19.2 years). Age, sex, white blood cell, hemoglobin, platelet, C-  
16 reactive protein, and D-dimer levels were most strongly associated with AKI and/or  
17 death. We created risk scores using these variables predicting AKI within 3 days and  
18 death within 30 days of a new COVID-19 diagnosis. Area under the curve (AUC) for  
19 predicting AKI within 3 days was 0.785 (95% CI, 0.758 to 0.813) and AUC for death  
20 within 30 days was 0.861 (95% CI, 0.843 to 0.878). Hemoglobin was the most predictive  
21 component for AKI, and age the most predictive for death. Predictive accuracies using  
22 all study variables were similar to using the simplified scores.

1 **Conclusion:** Simple risk scores using age, sex, a complete blood cell count, C-reactive  
2 protein, and D-dimer were highly predictive of AKI and death and can help simplify and  
3 better inform clinical decision making.

4 **Key words:** COVID-19; kidney injury; risk prediction

### 6 **Strengths and limitations of this study**

- 7 • Various associations between patient variables and COVID-19 acute kidney  
8 injury AKI and death have been reported, but it is unclear which variables are  
9 most predictive and important to focus on.
- 10 • We developed risk scores for predicting AKI and death among new COVID-19  
11 positive patients.
- 12 • Readily obtainable demographic, vital sign, and laboratory values were  
13 considered evaluated.
- 14 • Findings are limited to patients without chronic kidney disease.

## 1 Introduction

2 Although respiratory failure and diffuse inflammatory lung tissue damage are key  
3 features of coronavirus disease 2019 (COVID-19), involvement of other organs such as  
4 the kidneys has been well documented. Pathologic autopsy examinations of COVID-19  
5 kidneys have shown clusters of coronavirus-like particles in the tubular epithelium and  
6 podocytes, upregulation of the severe acute respiratory syndrome coronavirus 2  
7 (SARS-CoV-2) receptor angiotensin-converting enzyme 2 and positive immunostaining  
8 with SARS-CoV-2 nucleoprotein antibodies.<sup>1,2</sup> Hemodynamic instability, systemic  
9 hypoxia, abnormal coagulation, and inflammation from severe COVID-19 can also  
10 directly contribute to acute kidney injury (AKI) and induce acute tubular necrosis.<sup>3</sup>

11 Various epidemiologic studies from China, Europe, and the United States have  
12 investigated AKI outcomes among COVID-19 patients. Early studies in China have  
13 reported AKI incidences ranging from 0.5-15% among hospitalized and outpatient  
14 COVID-19 patients.<sup>4,5</sup> One United Kingdom study found hospitalized COVID-19 patients  
15 with AKI had a 3-fold higher odds of death than those without AKI.<sup>6</sup> Large US population  
16 studies of hospitalized COVID-19 patients, primarily in the New York City metropolitan  
17 area, have reported AKI incidences ranging from 27-57%, with in-hospital mortality rates  
18 ranging from 35-71% among AKI COVID-19 patients.<sup>7-10</sup> Some of these studies have  
19 also explored variable associations with COVID-19 AKI, but none of these studies have  
20 investigated which subset of these variables are most predictive of AKI or built risk  
21 predictions models using demographic variables and biomarkers.

22 Risk prediction tools have been investigated for COVID-19 deaths. A small  
23 number of a priori determined biomarkers were investigated for their associations with

1 the risk of COVID-19 death.<sup>11</sup> However, a more data driven approach would compare  
2 the predictive accuracies of these biomarkers to other biomarkers and variables such as  
3 demographic factors and vital signs and build a more powerful risk prediction model  
4 using a comprehensive set of biomarkers, demographic variables, and vital signs.  
5 Different risk factors should also be weighted differently, and understanding the relative  
6 importance of different variables in predicting poor outcomes will allow for more  
7 accurate holistic patient evaluations.

8 In this study we developed and evaluated new risk assessment tools that can be  
9 easily implemented at the bedside or during chart reviews to predict AKI and death after  
10 a positive COVID-19 test. Our contributions include (1) identifying the top biomarkers  
11 and demographic variables that predict AKI events among COVID-19 patients, (2)  
12 investigating a greater number of potential biomarkers and risk factors in predicting  
13 death, (3) developing clinical risk assessment tools for both AKI and death using a small  
14 number of predictors, and (4) validating that these tools are nearly as predictive as  
15 using all available study variables. By understanding which subset of risk factors are  
16 most important to focus on, medical providers can more efficiently work up and risk  
17 stratify their newly diagnosed COVID-19 patients.

## 19 **Methods**

### 20 *Study Population*

21 The Mass General Brigham (MGB) Health system serves a large diverse patient  
22 population around Boston and Eastern Massachusetts. Electronic health records from

1 three major hospitals in this system (Massachusetts General Hospital in Boston,  
2 Brigham and Women's Hospital in Boston, and Newton-Wellesley Hospital in Newton)  
3 were used. The Mass General Brigham Institutional Review Board approved this study,  
4 and the approval number was 2020P001661.

5 We included all patients that 1) were at least 18 years old, 2) tested COVID-19  
6 positive at one of the three hospitals above between February 1, 2020 through May 28,  
7 2020, and 3) had at least 2 serum creatinine tests within 30 days of their SARS-Cov-2  
8 PCR test. We excluded patients that 1) met the criteria of acute kidney injury within 3  
9 months before their SARS-CoV-2 test and 2) had chronic kidney disease (CKD)  
10 identified as a preexisting condition from International Classification of Disease (ICD-9  
11 and ICD-10) codes (see below).

### 12 13 *Patient and Public Involvement*

14 Patients and the public were not involved in the planning of this project.

### 15 16 *Data Collection*

17 Information in electronic health records (EHR) of patients who met the inclusion  
18 criteria were extracted from the enterprise data warehouse and included demographic,  
19 comorbidities, clinical, laboratory, and outcome data (death). Demographic and  
20 laboratory data information closest to the time of first SARS-Cov-2 PCR test were kept  
21 (except for serum creatinine, multiple values were kept). Serum creatinine laboratory

1 test results and timestamps within 3 months before and 30 days after the SARS-Cov-2  
2 polymerase chain reaction test were extracted. We categorized ethnic groups other than  
3 White, Black, Hispanic, and Asian into a single subgroup. All documented comorbidity  
4 related medical history in MGB healthcare system enterprise data warehouse before the  
5 first time of SARS-Cov-2 test were extracted. Preexisting conditions, including  
6 hypertension, diabetes, cardiovascular disease, and heart failure, were classified using  
7 their ICD-9 or ICD-10 codes.

### 8 9 *Definitions of Outcomes*

10 Per the Kidney Disease Improving Global Outcomes (KDIGO) criteria, AKI was  
11 defined as a change in serum creatinine (SCr) of 0.3 mg/dl over a 48-hour period, a  
12 50% increase in baseline creatinine in 7 days, or urine value <0.5 ml/kg/hour for 6  
13 hours.<sup>12</sup> Due to difficulties obtaining accurate urine volumes from electronic health  
14 record data, we only use serum creatinine to define AKI events. If patients had more  
15 than 2 SCr tests in their EHR, we used all available SCr tests to define the earliest time.  
16 Death times were directly extracted from the data warehouse.

### 17 18 *Statistical Analyses*

19 Continuous variables were transformed into categorical variables to improve  
20 interpretability of results and account for nonlinear associations. Counts and  
21 percentages were presented, and two proportion z-tests were used to compare the  
22 proportion of deaths among AKI and non-AKI patients. For AKI survival analyses,

1 observations without AKI were censored after 30 days, at the time of death, or at  
2 5/28/2020, whichever came first. For death survival analyses, observations without  
3 death were censored at 5/28/2020. Multiple multivariable Cox proportional hazards  
4 models included age, sex, race, diabetes, cardiovascular disease, hypertension, heart  
5 failure, body mass index (BMI), temperature, heart rate, systolic blood pressure, white  
6 blood cell count (WBC), hemoglobin, platelets, C-reactive protein (CRP), ferritin, D-and  
7 dimer. Respiratory rate and interleukin-6 (IL-6) variables were not included in primary  
8 analyses given missing data. However, we performed exploratory analyses imputing the  
9 missing respiratory rate and IL-6 values (additional details are in the sensitivity analysis  
10 section).

11 We next built a simplified Cox model for clinical use by using a stepwise variable  
12 selection procedure for Cox models alternating between “forward” and “backwards”  
13 steps to identify the first 5 variables to be included.<sup>13</sup> Simplified Cox models were fit  
14 using only the selected 5 variables and Harrell’s C-Statistics were obtained (survival  
15 outcome). Model coefficient (linear prediction) accuracy was evaluated. We evaluated  
16 area under receive operating characteristic (ROC) curves (AUC) for predicting AKI  
17 within 3 days and death within 30 days of a new COVID-19 diagnosis (binary outcome).  
18 Net reclassification improvement (NRI) of adding all remaining covariates was also  
19 calculated.

20 Risk scores were obtained by rounding simplified model coefficients for easier  
21 clinical risk assessment use. For suggested risk score cutoffs, Kaplan-Meier event  
22 curves were plotted, log rank tests were performed, and sensitivities, specificities,  
23 positive and negative likelihood ratios were calculated. Approximate pre-test to post-test



1 probability changes from likelihood ratios were calculated using the linear approximation  
2 proposed by McGee.<sup>14</sup> Cutoffs for low risk were chosen so that the negative likelihood  
3 ratio would be  $\approx 0.20$  with a pre- to post-test probability decrease of  $\approx 30\%$ , while cutoffs  
4 for high risk were chosen so that the positive likelihood ratio would be  $\approx 5.0$  with a pre- to  
5 post-test probability increase of  $\approx 30\%$  and that at least 15% of patients (560) would be  
6 identified as high risk.<sup>14</sup> We ran 1,000 internal cross validation iterations in which 70% of  
7 data were randomly assigned to training, the other 30% to testing. For each iteration,  
8 simplified Cox models were fit to the training data, coefficients were rounded to obtain  
9 risk scores, and AUC's were calculated using the predicted testing data risk scores.

10 We performed four sensitivity analyses. First, the multivariable cause-specific  
11 and subdistribution hazard to documented AKI events within 30 days accounting for the  
12 competing risk of death was modeled.<sup>15</sup> Second, we performed a multiple imputation  
13 analysis by creating 10 imputation datasets with imputed values for missing respiratory  
14 rate and IL-6 and then calculating pooled multivariable Cox hazard ratios.<sup>16</sup> Third, we  
15 investigated the AKI risk score accuracy in identifying stage 2 or 3 AKI as defined in the  
16 KDIGO criteria, and we investigated the death score accuracy among patients with  
17 stage 2 or 3 AKI.<sup>12</sup> Fourth, we investigated including mechanical ventilation  
18 (noninvasive and invasive) and lymphopenia defined as lymphocytes  $< 800$  cells/mm<sup>3</sup> as  
19 covariates for modeling AKI and death events. All analyses were performed with R  
20 version 4.0.4 and all code for analyses are available online (to be posted during  
21 revisions).

## 22 23 **Results**

## 1 *Demographic and Clinical Characteristics*

2           There were 3,716 eligible adult COVID-19 positive patients without CKD, of  
3 which 1,855 (49.9%) were male. The average age was 58.6 years (SD 19.2 years).

4           There were 696 patients that developed AKI (18.7%) and 249 (35.8%) were within three  
5 days of a new COVID-19 diagnosis. There were 347 deaths (9.3%) and 322 (92.8%)  
6 were within thirty days of a new COVID-19 diagnosis. Among the AKI group there were  
7 192 deaths (27.6%), and among the non-AKI group there were 155 deaths (5.1%,  
8  $p<0.001$ ). Patient demographics, preexisting conditions, vital signs, and laboratory  
9 values stratified by patients with AKI and patients that died are displayed in **Table 1**.

10          Patients with AKI and patients that died were more likely to be older, male, have  
11 multiple comorbidities, and have on admission higher temperatures, lower systolic blood  
12 pressures, higher respiratory rates, elevated white blood cell counts, lower hemoglobin  
13 and platelets, and elevated CRP, ferritin, D-dimer, and IL-6 levels.

## 15 *Fully Adjusted Multivariable Regression*

16          Multivariable Cox regression was performed to identify risk factors associated  
17 with time to AKI and death. **Table 2** displays pooled multivariable adjusted hazard  
18 ratios. Adjusting for all other variables, older age, increased medical conditions,  
19 increased temperature, decreased systolic blood pressure, increased white blood cells,  
20 decreased platelets, and increased CRP and D-Dimer were associated with increased  
21 hazards for both AKI and death. Elevated BMI, decreased hemoglobin, and increased  
22 ferritin were associated with increased hazards for AKI but not death. Black and Asian

1 race were associated with decreased hazards and increased heart rate was associated  
2 with increased hazards for death but not AKI.

3

#### 4 *Top Risk Factor/Biomarker Selection*

5 The top five variables selected for being most associated with AKI events were  
6 hemoglobin, D-dimer, CRP, WBC, and male sex. The top five variables most associated  
7 with death were age, CRP, platelets, WBC, and D-Dimer. **Table S1** shows model  
8 coefficients and Harrell's C-statistic (survival concordance) from the simplified model  
9 using just these selected variables. **Table S2** shows similar results for the fully adjusted  
10 model. The simplified AKI Cox model had a survival C-statistic of 0.785 (95% CI, 0.769  
11 to 0.800), while the fully adjusted AKI Cox model had a C-statistic of 0.813 (95% CI,  
12 0.798 to 0.827). The simplified death Cox model had a survival C-statistic of 0.857 (95%  
13 CI, 0.841 to 0.874), while the fully adjusted death Cox model had a C-statistic of 0.878  
14 (95% CI, 0.863 to 0.892).

15 Cox model coefficients were used to predict AKI events within 3 days and death  
16 within 30 days of a new COVID-19 diagnosis (binary outcomes). **Table S1** and **Table**  
17 **S2** also displays AUC's for the simplified and fully adjusted coefficients respectively. For  
18 AKI in 3 days, using the simplified coefficients had an AUC of 0.787 (95% CI, 0.759 to  
19 0.814), using the fully adjusted coefficients had an AUC of 0.820 (95% CI, 0.794 to  
20 0.845), and the NRI was 0.041 (95% CI, 0.003 to 0.082). For death in 30 days, using  
21 the simplified coefficients had an AUC of 0.872 (95% CI, 0.854 to 0.890), the fully

1 adjusted coefficients had an AUC of 0.893 (95% CI, 0.878 to 0.909), and the NRI was  
2 0.010 (95% CI, -0.007 to 0.029).

3

#### 4 *Risk Score*

5 Model coefficients were rounded to obtain risk score component values for easier  
6 clinical use. **Table 3** shows the risk score and internal validation results. For AKI in 3  
7 days, the risk score had an AUC 0.785 (95% CI, 0.758, 0.813) and a cross validation  
8 AUC of 0.776 (95% CI, 0.732, 0.816). For death in 30 days, the risk score had an AUC  
9 of 0.861 (95% CI, 0.843 to 0.878) and a cross validation AUC of 0.860 (95% CI, 0.831,  
10 0.886). **Figure 1A** plots ROC curves for using fully adjusted coefficients (from **Table S2**)  
11 versus using risk scores (from **Table 3**) in predicting AKI in 3 days and death in 30  
12 days.

13 Suggested risk stratification cutoffs were obtained. **Table S3** presents sensitivity,  
14 specificity, and positive and negative likelihood ratios for all possible risk score cutoffs.  
15 **Table 4** shows suggested risk stratification cutoffs and stratified observed and  
16 estimated event rates. Higher risk scores had higher observed and estimated AKI and  
17 death rates. **Figure 1B** plots Kaplan Meier event curves of AKI and death events by  
18 simplified risk score categories. Event rates different by risk category for AKI ( $p<0.001$ )  
19 and death ( $p<0.001$ ).

20

#### 21 *Sensitivity Analysis*

1 We performed a competing risk regression analysis for AKI and death within 30  
2 days. **Table S4** displays the multivariable cause-specific and subdistribution hazard  
3 ratios for AKI events. Cause-specific and subdistribution hazard ratio estimates and  
4 confidence intervals were nearly identical. We also performed a multiple imputation  
5 analysis by imputing missing values for respiratory rate and IL-6 to evaluate their  
6 associations. **Table S5** shows that results were similar to non-imputation results, and  
7 increased respiratory rate and IL-6 were associated with increased hazards of AKI and  
8 death.

9 Of the 696 patients with an AKI event, 580 had a stage 1 AKI (83.3%), 29 had  
10 stage 2 (4.2%), and 87 had stage 3 (12.5%). Of the 117 patients with stage 2 or 3 AKI,  
11 there were 39 deaths (33.6%). In predicting stage 2 or 3 AKI as a single composite  
12 outcome among all 3,716 patients, the AKI risk score in **Table 3** had an AUC of 0.850  
13 (95% CI, 0.819 to 0.881). In predicting death among the 117 patients with stage 2 or 3  
14 AKI, the death risk score in **Table 3** had an AUC of 0.758 (95% CI, 0.671 to 0.846).

15 Of the 696 patients with an AKI event, 207 (29.7%) had lymphopenia with  
16 lymphocytes  $<800$  cells/mm<sup>3</sup> and 328 (47.1%) had received mechanical ventilation. Of  
17 the 347 patients with a death event, 150 (43.2%) had lymphopenia and 124 (35.7%)  
18 had received mechanical ventilation. Of all 3,716 patients, 690 (18.6%) had  
19 lymphopenia and 449 (12.1%) had received mechanical ventilation. For AKI in 3 days,  
20 the fully adjusted coefficients in the primary analyses had an AUC of 0.820 (95% CI,  
21 0.794 to 0.845) while additionally adding lymphopenia and mechanical ventilation only  
22 increased the AUC to 0.838 (95% CI, 0.814, 0.861). For death in 30 days, the fully  
23 adjusted coefficients had an AUC of 0.893 (95% CI, 0.878 to 0.909), while additionally

1  
2  
3 1 adding lymphopenia and mechanical ventilation only increased the AUC to 0.906 (95%  
4  
5 2 CI, 0.893 to 0.920).  
6  
7  
8  
9 3

#### 11 4 **Discussion**

14 5 In this retrospective study of over 3,700 adult patients without chronic kidney  
15  
16 6 disease diagnosed with COVID-19 through May 2020 in the Boston area, we identified  
17  
18 7 risk factors and biomarkers associated with AKI and death, and we developed and  
19  
20 8 internally validated risk scores for predicting AKI and death. We found about one in five  
21  
22 9 patients developed AKI and one in ten patients died. Increased age, male sex,  
23  
24 10 increased white blood cells, C-reactive protein and D-Dimer and decreased hemoglobin  
25  
26 11 and platelet levels were associated with AKI within 3 days and/or death within 30 days  
27  
28 12 of a new COVID-19 diagnosis. A risk score using just these variables had similar  
29  
30 13 internal accuracy as using all study variables. These results can assist in risk  
31  
32 14 stratification of COVID-19 patients without CKD.  
33  
34  
35  
36  
37

38 15 Many studies have found markedly increased COVID-19 fatality rates among  
39  
40 16 older people. Studies from China, Spain, and Italy, and a meta-analysis of studies from  
41  
42 17 34 different geographical locations have all found increased case or infection fatality  
43  
44 18 rates among people >60 and >65 years old compared to younger populations.<sup>17–20</sup> We  
45  
46 19 similarly observed older age had some of the strongest associations with death. Earlier  
47  
48 20 studies have found various physiologic changes among elderly patients that may  
49  
50 21 contribute to this age-related risk, such as decreased small airway clearance,  
51  
52 22 decreased number of cilia and ciliated cells, and decreased upper airway size.<sup>21–23</sup>  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 Other studies have also reported worse COVID-19 outcomes among men. A  
4  
5 2 study of over 3,300 patients in Montefiore Medical Center found male sex was  
6  
7 3 associated with AKI in both COVID-19 positive and negative patients.<sup>8</sup> This study also  
8  
9 4 provided a more complete discussion of other animal studies and meta-analyses to date  
10  
11 5 that that have found associations between male sex and AKI in general. Studies of  
12  
13 6 COVID-19 outcomes from March 2020 in Italy and the US also reported increased  
14  
15 7 hospitalization and intensive care unit admission rates among male patients.<sup>24,25</sup> We  
16  
17 8 similarly observed that AKI patients (60.3%) and patients that died (58.2%) were more  
18  
19 9 likely to be male (overall 49.9%). However, after adjusting for other demographics,  
20  
21 10 medical conditions, vital signs, and laboratory values, we found male sex was  
22  
23 11 associated with AKI but not death.

24  
25  
26  
27  
28  
29 12 Among laboratory values, C-reactive protein, hemoglobin, white blood cells, D-  
30  
31 13 Dimer, and platelets were significantly associated with AKI and death and were included  
32  
33 14 in risk scores. Although there has been debate about a standard definition for COVID-  
34  
35 15 19 cytokine storm syndrome, patients with C-reactive protein may have excessive  
36  
37 16 immune activation, with C-reactive protein being produced by hepatocytes in response  
38  
39 17 to IL-6 or ferritin.<sup>26</sup> Decreased hemoglobin may be reflective of kidney disease with  
40  
41 18 decreased erythropoietin production or directly lead to decreased oxygenation of the  
42  
43 19 kidneys. A study from Korea also found a higher risk of AKI in critically ill patients with a  
44  
45 20 hemoglobin <10.5 g/dL.<sup>27</sup> Elevated white blood cell counts may suggest sepsis and be  
46  
47 21 associated with life-threatening organ dysfunction.<sup>28</sup> Elevated D-Dimer levels may be  
48  
49 22 indicative of a pro-thrombotic state, and a retrospective study from China found that D-  
50  
51 23 Dimer >2000 ng/mL was associated with increased mortality.<sup>29</sup> However D-dimer levels

1 have also been reported to be elevated at baseline in CKD patients,<sup>30</sup> so it is possible  
2 elevated D-Dimer may only be prognostic in non-CKD patients. Low platelets may also  
3 indicate a systemic coagulopathic process that places patients at an increased risk for  
4 death.<sup>28</sup>

5 The biomarker IL-6 was found to be a significant risk factor in regression  
6 analyses. However, a substantial proportion of patients in our study were missing IL-6  
7 values (78.3%), so IL-6 was not considered for risk score development. IL-6  
8 measurements were obtained at physician discretion and were likely reserved for  
9 severe cases. This may have also contributed to the missingness profile of IL-6.  
10 Previous studies have found IL-6 cutoffs of 80 and 86 IU/mL to have prognostic value  
11 for predicting respiratory failure and death respectively.<sup>31,32</sup>

12 We proposed risk scores for identifying AKI within 3 days and death within 30  
13 days of a new COVID-19 diagnosis along with suggested cutoffs. Although risk scores  
14 still need to be externally validated, being able to identify a few key biomarkers that are  
15 widely accessible can help focus chart reviews of new COVID-19 positive patients.  
16 Varying score weights further highlight biomarkers to focus on, such as hemoglobin and  
17 male sex for AKI, age and platelets for death, and WBC, CRP, and D-Dimer for both.  
18 Larger scores directly correlate with worse outcomes and can help shape physician  
19 gestalt.

20 We explored death being a competing risk for AKI events as patients with death  
21 will not have any more creatinine measurements. Although an AKI does not exclude the  
22 possibility of death, competing risk analyses can still be performed investigating which  
23 event type occurs first.<sup>15</sup> The cause-specific hazards ratios (Cox hazard ratios) describe



1 the rate of AKI events among those still alive and with no previous AKI events, while the  
2 subdistribution hazard ratios describes the overall rate of AKI events occurring before  
3 death. In our study both cause-specific and subdistribution hazard ratios were similar.  
4 Competing risk analyses were not performed for death events as having an AKI does  
5 not exclude death.

6 We looked at a subgroup of patients which developed stage 2 or 3 AKI. Our AKI  
7 risk score also performed well in identifying patients who developed stage 2 or 3 AKI,  
8 suggesting higher risk scores also correlate with developing a higher stage AKI. Among  
9 patients who developed stage 2 or 3 AKI, the death risk score AUC had a larger  
10 confidence interval likely because of the smaller sample size and smaller number of  
11 death events.

12 We explored including lymphopenia and mechanical ventilation as variables in  
13 analyses. Lymphopenia has been found to be associated with greater COVID-19  
14 disease severity and poorer outcomes,<sup>33</sup> and hypoxemia requiring mechanical  
15 ventilation may affect kidney perfusion and also lead to poorer outcomes. We found that  
16 additionally including lymphopenia and mechanical ventilation to our study variables  
17 only led to small improvements in AUC in predicting AKI and death events.  
18 Nonetheless, we expect that patients who score high on our risk scores but also have  
19 lymphopenia and/or require mechanical ventilation will be at even greater risk of AKI  
20 and death events. Future work can further investigate including these variables into risk  
21 scores.

22 Limitations to our study include the following. All results are associational and no  
23 causal effects should be interpreted. Vital and signs and laboratory values were those

1 closest to COVID-19 diagnosis, and time-varying covariates were not incorporated into  
2 analyses. As the study was retrospective, selection bias cannot be excluded, and only  
3 events within the MGB system were recorded. Our identified risk factors and risk scores  
4 are most applicable during a patient's initial COVID-19 positive test. Results may not be  
5 generalizable to more specific subgroups such as those requiring intensive care  
6 admission. Patients in the Boston area may not be reflective of those in other healthcare  
7 systems, and the study population included only COVID-19 positive patients without  
8 CKD. The study population included patients in the first wave of COVID-19, and results  
9 should be cautiously applied to subsequent waves of COVID-19 due to differences in  
10 COVID-19 variants and treatment protocols. Future work may further stratify AKI events  
11 by stage and time of acquisition (relative to hospital admission), investigate outpatient,  
12 hospitalized, and critically ill patients separately, focus on CKD patients, validate results  
13 on a separate cohort, explore hospital specific effects, and include medication use such  
14 as renin-angiotensin-aldosterone system inhibitors.

15 We investigated AKI and death outcomes among adult COVID-19 patients  
16 without CKD in the Boston area. We identified risk factors and developed and evaluated  
17 risk assessment tools for identifying COVID-19 patients developing AKI and death.  
18 Hemoglobin, D-Dimer, CRP, WBC, and male sex were the strongest predictive  
19 biomarkers for AKI. Age, CRP, platelets, WBC, and D-Dimer were most predictive for  
20 death. Our study significantly contributes to epidemiological knowledge of COVID-19  
21 outcomes and introduces simple tools to assist with rapid risk assessment.

22

## 23 **Acknowledgements**

1 **Contributors:** None

2 **Funding statement:** This work was supported by the National Institutes of Health grant  
3 number T32-GM135117 (DL).

4 **Competing interests:** The authors declare no relevant competing interests.

5 **Authors' contributions:** DL and HR drafted the manuscript. HR, PX, DW obtained the  
6 data. DL performed the analyses. DL, HR, DJV, PS, QL, and XL contributed to the  
7 design of the study. All authors were involved with interpretation of the data and critical  
8 revision and final approval of the article.

9 **Availability of data and materials:** Patient data is not available, but requests for  
10 surrogate data may be made to the corresponding authors. However, code for all  
11 analyses will be available at <https://github.com/lin-lab>.

12 **Patient and public involvement:** Patients and the public were not involved in the  
13 planning of this project.

14 **Research ethics approval human subjects:** The Mass General Brigham Institutional  
15 Review Board approved this study, and the approval number was 2020P001661. Only  
16 deidentified patient electronic health record data were used.

17

## References

1. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. 2020;98(1):219-227. doi:10.1016/j.kint.2020.04.003
2. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. *JASN*. 2020;31(8):1683-1687. doi:10.1681/ASN.2020040432
3. Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol*. Published online October 15, 2020. doi:10.1038/s41581-020-00356-5
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
5. Guan W jie, Ni Z yi, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
6. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. Remuzzi G, ed. *PLoS Med*. 2020;17(10):e1003406. doi:10.1371/journal.pmed.1003406
7. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney International*. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
8. Fisher M, Neugarten J, Bellin E, et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. *JASN*. 2020;31(9):2145-2157. doi:10.1681/ASN.2020040509
9. Zahid U, Ramachandran P, Spitalewitz S, et al. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications. *Am J Nephrol*. 2020;51(10):786-796. doi:10.1159/000511160
10. Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. *JASN*. 2021;32(1):151-160. doi:10.1681/ASN.2020050615
11. Smilowitz NR, Nguy V, Aphinyanaphongs Y, et al. Multiple Biomarker Approach to Risk Stratification in COVID-19. *Circulation*. Published online February 15, 2021:CIRCULATIONAHA.120.053311. doi:10.1161/CIRCULATIONAHA.120.053311

12. *KDIGO Clinical Practice Guideline for Acute Kidney Injury*. Kidney Disease Improving Global Outcomes; 2012:1-141. Accessed January 8, 2021. <https://linkinghub.elsevier.com/retrieve/pii/S2157171615310388>
13. Hu FC. My.stepwise.coxph, Stepwise Variable Selection Procedure For Cox's Proportional Hazards Model And Cox's Model. R Documentation. Accessed February 23, 2021. <https://www.rdocumentation.org/packages/My.stepwise/versions/0.1.0/topics/My.stepwise.coxph>
14. McGee S. Simplifying likelihood ratios. *J Gen Intern Med*. 2002;17(8):647-650. doi:10.1046/j.1525-1497.2002.10750.x
15. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719
16. Rubin DB. Inference and Missing Data. *Biometrika*. 1976;63(3):581-592.
17. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious Diseases*. 2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7
18. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ*. Published online November 27, 2020:m4509. doi:10.1136/bmj.m4509
19. Signorelli C, Odone A. Age-specific COVID-19 case-fatality rate: no evidence of changes over time. *Int J Public Health*. 2020;65(8):1435-1436. doi:10.1007/s00038-020-01486-0
20. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol*. 2020;35(12):1123-1138. doi:10.1007/s10654-020-00698-1
21. Martin SE, Mathur R, Marshall I, Douglas NJ. The effect of age, sex, obesity and posture on upper airway size. *European Respiratory Journal*. 1997;10(9):2087-2090. doi:10.1183/09031936.97.10092087
22. Svartengren M. Long-term clearance from small airways decreases with age. *European Respiratory Journal*. 2005;26(4):609-615. doi:10.1183/09031936.05.00002105
23. Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. *Aging Clin Exp Res*. 2020;32(8):1599-1608. doi:10.1007/s40520-020-01631-y

- 1  
2  
3 1 24. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of  
4 2 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy  
5 3 Region, Italy. *JAMA*. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394  
6  
7  
8 4 25. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of  
9 5 Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 —  
10 6 COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep*.  
11 7 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3  
12  
13 8 26. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the  
14 9 controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur Respir*  
15 10 *J*. 2020;56(4). doi:10.1183/13993003.03006-2020  
16  
17  
18 11 27. Han SS, Baek SH, Ahn SY, et al. Anemia Is a Risk Factor for Acute Kidney Injury  
19 12 and Long-Term Mortality in Critically Ill Patients. *Tohoku J Exp Med*.  
20 13 2015;237(4):287-295. doi:10.1620/tjem.237.287  
21  
22 14 28. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,  
23 15 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-  
24 16 19): A Review. *JAMA*. 2020;324(8):782. doi:10.1001/jama.2020.12839  
25  
26  
27 17 29. Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and  
28 18 mortality in COVID-19 patients: a case control study. *J Intensive Care*. 2020;8.  
29 19 doi:10.1186/s40560-020-00466-z  
30  
31 20 30. Lindner G, Funk GC, Pfortmueller CA, et al. D-dimer to Rule Out Pulmonary  
32 21 Embolism in Renal Insufficiency. *The American Journal of Medicine*.  
33 22 2014;127(4):343-347. doi:10.1016/j.amjmed.2013.12.003  
34  
35  
36 23 31. Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the  
37 24 need for mechanical ventilation in COVID-19. *Journal of Allergy and Clinical*  
38 25 *Immunology*. 2020;146(1):128-136. doi:10.1016/j.jaci.2020.05.008  
39  
40 26 32. Laguna-Goya R, Utrero-Rico A, Talayero P, et al. IL-6–based mortality risk model  
41 27 for hospitalized patients with COVID-19. *Journal of Allergy and Clinical*  
42 28 *Immunology*. 2020;146(4):799-807.e9. doi:10.1016/j.jaci.2020.07.009  
43  
44 29 33. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-  
45 30 19): systematic review and meta-analysis. *J Intensive Care*. 2020;8(1):36.  
46 31 doi:10.1186/s40560-020-00453-4  
47  
48  
49 32  
50  
51  
52 33  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Figure Legends**  
4

5 **2 Fig. 1 Receiver Operating Characteristics and Kaplan Meier Event Curves Using**  
6 **3 Selected Variables.**  
7

8 **(A)** Receiver operating characteristic (ROC) curves for acute kidney injury (AKI) within 3  
9 days and death within 30 days using fully adjusted model coefficients and developed  
10 risk score. Each line represents a different model's predictions with the given variables.  
11 HGB = Hemoglobin, CRP = C-reactive protein, WBC = white blood cell, PLT = Platelets.  
12  
13

14 **(B)** Kaplan-Meier event curves for AKI events and death events stratified by AKI and  
15 death scores. Time begins at positive COVID-19 test.  
16  
17

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Table 1.** Characteristics of Patients with Acute Kidney Injury, Patients that Died, and All  
 2 Patients.

Variable, n (%)	AKI (n=696)	Died (n=347)	Total (n=3,716)
Age (years)			
<45	86 (12.4)	7 (2.0)	980 (26.4)
45-65	245 (35.2)	55 (15.9)	1,310 (35.3)
>65	365 (52.4)	285 (82.1)	1,426 (38.4)
Sex (Male)	420 (60.3)	202 (58.2)	1,855 (49.9)
Race			
White	407 (58.5)	242 (69.7)	2,091 (56.3)
Black	110 (15.8)	50 (14.4)	568 (15.3)
Hispanic	22 (3.2)	9 (2.6)	135 (3.6)
Asian	27 (3.9)	8 (2.3)	140 (3.8)
Other	130 (18.7)	38 (11.0)	782 (21.0)
Diabetes	197 (28.3)	87 (25.1)	727 (19.6)
Cardiovascular Disease	67 (9.6)	49 (14.1)	231 (6.2)
Hypertension	135 (19.4)	65 (18.7)	484 (13.0)
Heart Failure	39 (5.6)	38 (11.0)	134 (3.6)
Medical Conditions (number)			
0	397 (57.0)	189 (54.5)	2,565 (69.0)
1	190 (27.3)	95 (27.4)	811 (21.8)
2	83 (11.9)	47 (13.5)	264 (7.1)
3+	26 (3.7)	16 (4.6)	76 (2.0)
Body Mass Index (kg/m <sup>2</sup> )			
<25	165 (23.7)	115 (33.1)	833 (22.4)
25-30	229 (32.9)	110 (31.7)	1,334 (35.9)
>30	302 (43.4)	122 (35.2)	1,549 (41.7)
Temperature (F)			
97-100.4	423 (60.8)	201 (57.9)	2,745 (73.9)
<97	35 (5.0)	22 (6.3)	190 (5.1)
>100.4	238 (34.2)	124 (35.7)	781 (21.0)
Heart Rate (beats/min)			
60-110	576 (82.8)	274 (79.0)	3,194 (86.0)
<60	61 (8.8)	30 (8.6)	275 (7.4)
>110	59 (8.5)	43 (12.4)	247 (6.6)
Systolic Blood Pressure (mmHg)			
90-180	635 (91.2)	305 (87.9)	3,549 (95.5)
<90	48 (6.9)	35 (10.1)	117 (3.1)
>180	13 (1.9)	7 (2.0)	50 (1.3)
Respiratory Rate (per minute)			



<20	245 (35.2)	92 (26.5)	1,692 (45.5)
>20	364 (52.3)	202 (58.2)	1,237 (33.3)
NA (Missing)	87 (12.5)	53 (15.3)	787 (21.2)
White Blood Cell (thousand cells/mm <sup>3</sup> )			
3.5-11	428 (61.5)	189 (54.5)	2,942 (79.2)
<3.5	39 (5.6)	26 (7.5)	267 (7.2)
>11	229 (32.9)	132 (38.0)	507 (13.6)
Hemoglobin (g/dL)			
12+	201 (28.9)	138 (39.8)	2,250 (60.5)
10-12	204 (29.3)	88 (25.4)	883 (23.8)
<10	291 (41.8)	121 (34.9)	583 (15.7)
Platelets (per $\mu$ L)			
>100	643 (92.4)	310 (89.3)	3,600 (96.9)
<100	53 (7.6)	37 (10.7)	116 (3.1)
C-Reactive Protein (mg/L)			
<50	197 (28.3)	62 (17.9)	1,706 (45.9)
50-100	149 (21.4)	63 (18.2)	1,011 (27.2)
>100	350 (50.3)	222 (64.0)	999 (26.9)
Ferritin ( $\mu$ g/L)			
<250	105 (15.1)	52 (15.0)	950 (25.6)
250-1000	327 (47.0)	155 (44.7)	1,894 (51.0)
>1000	264 (37.9)	140 (40.3)	872 (23.5)
D-Dimer (ng/mL)			
<1000	136 (19.5)	60 (17.3)	1,726 (46.4)
1000-2000	217 (31.2)	101 (29.1)	1,076 (29.0)
>2000	343 (49.3)	186 (53.6)	914 (24.6)
Interleukin-6 (IU/mL)			
<40	121 (17.4)	26 (7.5)	438 (11.8)
40-80	68 (9.8)	33 (9.5)	137 (3.7)
>80	136 (19.5)	58 (16.7)	196 (5.3)
NA (Missing)	371 (53.3)	230 (66.3)	2,945 (79.3)

AKI = acute kidney injury

1 **Table 2.** Multivariable Cox Regression Results.

Variable	AKI	Death
Age (years)		
<45	Reference	Reference
45-65	<b>1.71 (1.33, 2.21)</b>	<b>5.33 (2.42, 11.8)</b>
>65	<b>2.16 (1.66, 2.80)</b>	<b>23.4 (10.9, 50.1)</b>
Sex (Male)	<b>1.51 (1.28, 1.77)</b>	1.16 (0.92, 1.45)
Race		
White	Reference	Reference
Black	0.89 (0.72, 1.11)	<b>0.66 (0.48, 0.92)</b>
Hispanic	0.89 (0.58, 1.38)	0.62 (0.32, 1.23)
Asian	0.96 (0.65, 1.43)	<b>0.46 (0.22, 0.93)</b>
Other	1.11 (0.90, 1.37)	0.72 (0.50, 1.02)
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.28 (1.07, 1.53)</b>	<b>1.07 (0.83, 1.38)</b>
2	<b>1.67 (1.30, 2.13)</b>	<b>1.40 (1.01, 1.95)</b>
3+	<b>1.82 (1.21, 2.75)</b>	<b>1.61 (0.95, 2.73)</b>
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.09 (0.89, 1.33)	0.78 (0.59, 1.02)
>30	<b>1.42 (1.17, 1.74)</b>	0.94 (0.72, 1.22)
Temperature (F)		
97-100.4	Reference	Reference
<97	1.07 (0.75, 1.51)	1.18 (0.75, 1.85)
>100.4	<b>1.59 (1.34, 1.88)</b>	<b>1.54 (1.22, 1.96)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.24 (0.95, 1.63)	0.97 (0.66, 1.43)
>110	1.11 (0.85, 1.47)	<b>1.78 (1.28, 2.48)</b>
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.90 (1.41, 2.57)</b>	<b>2.10 (1.45, 3.04)</b>
>180	0.96 (0.55, 1.67)	0.90 (0.42, 1.92)
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.78 (0.55, 1.09)	1.10 (0.72, 1.68)
>11	<b>1.77 (1.49, 2.12)</b>	<b>2.32 (1.82, 2.95)</b>
Hemoglobin (g/dL)		
>12	Reference	Reference
10-12	<b>2.15 (1.75, 2.64)</b>	0.88 (0.67, 1.16)
<10	<b>3.72 (3.03, 4.57)</b>	1.03 (0.78, 1.35)

Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.74 (1.30, 2.34)</b>	<b>2.60 (1.79, 3.77)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.96 (0.77, 1.20)	<b>1.46 (1.02, 2.10)</b>
>100	<b>1.57 (1.29, 1.91)</b>	<b>3.61 (2.65, 4.93)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	<b>1.29 (1.03, 1.63)</b>	0.91 (0.65, 1.26)
>1000	<b>1.69 (1.31, 2.17)</b>	1.14 (0.80, 1.62)
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.67 (1.33, 2.09)</b>	1.21 (0.87, 1.69)
>2000	<b>2.11 (1.68, 2.65)</b>	<b>1.82 (1.31, 2.52)</b>

1

1 **Table 3.** Risk Score and Internal Validation Results.

AKI in 3 days (max 6)		Death in 30 days (max 7)	
Risk Score			
Variable	Value	Variable	Value
Hemoglobin <10 g/dL	2	Age > 65 years	3
Hemoglobin 10-12 g/dL	1	Age 45-65 years	2
D-Dimer > 1,000 ng/mL	1	CRP > 100 mg/L	1
CRP > 100 mg/L	1	Platelets < 100 per $\mu$ L	1
WBC > 11,000 cells/mm <sup>3</sup>	1	WBC > 11,000 cells/mm <sup>3</sup>	1
Male Sex	1	D-Dimer > 2,000 ng/mL	1
Internal Validation			
Validation Type	AUC (95% intervals)	Validation Type	AUC (95% intervals)
Whole Data	0.785 (0.758, 0.813)	Whole Data	0.861 (0.843, 0.878)
Cross Validation	0.776 (0.732, 0.816)	Cross Validation	0.860 (0.831, 0.886)

2 CRP = C-reactive protein, WBC = white blood cells.

3 Whole data validation presents area under the curve (AUC) estimates and 95%  
4 confidence intervals.

5 Internal cross validation presents mean AUC and 95% central interval (2.5<sup>th</sup> and 97.5<sup>th</sup>  
6 percentiles).

7


1 **Table 4.** Suggested Risk Stratification Cutoffs and Observed and Estimated Event  
 2 Rates.

<b>AKI Risk Score</b>				
<b>Risk Level</b>	<b>Total Score</b>	<b>Observed Total AKI (%)</b>	<b>Estimated 3 Day AKI (%)</b>	<b>Estimated 30 Day AKI (%)</b>
Low Risk	0-1	5.2	1.7	5.4
Moderate Risk	2-3	18.4	6.2	19.7
High Risk	4-6	54.7	21.6	59.7
<b>Death Risk Score</b>				
<b>Risk Level</b>	<b>Total Score</b>	<b>Observed Total Death (%)</b>	<b>Estimated 30 Day Death (%)</b>	<b>Estimated 60 Day Death (%)</b>
Low Risk	0-3	1.7	1.6	2.0
Moderate Risk	4	10.4	10.2	12.3
High Risk	5-7	37.9	37.3	43.4

3 Observed percentages are from the observed data

4 Estimated percentages are from Kaplan-Meier event curves

5



(A) Receiver operating characteristic (ROC) curves for acute kidney injury (AKI) within 3 days and death within 30 days using fully adjusted model coefficients and developed risk score. Each line represents a different model's predictions with the given variables. HGB = Hemoglobin, CRP = C-reactive protein, WBC = white blood cell, PLT = Platelets.

(B) Kaplan-Meier event curves for AKI events and death events stratified by AKI and death scores. Time begins at positive COVID-19 test.

450x448mm (96 x 96 DPI)

## Supplemental Methods – Additional Details

### *Statistical Analyses*

Descriptive statistics and receiver operating characteristics (ROC) were calculated using R base functions. Cox proportional hazards models were fit using the “survival” package. Inspection of AKI and death Kaplan-Meier event curves stratified by each variable revealed no obvious violations of the proportional hazards assumption.

The variable selection procedure was implemented using the “My.stepwise” package. In addition to the variables included in fully adjusted Cox proportional hazards models, age >45 years, medical conditions >1, medical conditions >2, BMI > 25 kg/m<sup>2</sup>, hemoglobin <12 g/dL, CRP > 500 mg/L, ferritin >250 µg/L, and D-Dimer > 1,000 ng/mL were also included. The package “glmnet” was used to reformat data so that the variable selection procedure could be applied. The selection procedure alternates between “forward” steps of adding variables and “backwards” steps of removing variables. The significance level for entry and for staying was conservatively set at 0.15 as suggested by function details. The top 5 variables (top 6 dummy variables) were included in risk scores. Simplified risk score values were obtained by rounding model coefficients to the nearest integer.

ROC curves were created using “plotROC” and AUC values and confidence intervals were obtained from “pROC”. Event curves were created using “survminer” and “mstate”. Harrell’s C-statistics were obtained from Cox proportional hazards model output, and net reclassification of improvement was obtained from “nricens”.

1  
2  
3 Competing risk analyses used the “cmprsk” package, and multiple imputation  
4 analyses used the “mice” package. The packages “ggplot2”, “dplyr”, “plyr”, “ggfortify”,  
5  
6 and “cowplot” were used to process results and create figures. Code for replicating all  
7  
8 analyses will be available online.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Table S1.** Coefficients from simplified Cox regression models to calculated and internal validation statistics using these coefficient linear predictions.

AKI		Death	
Simplified Model Coefficients			
Variable	Coefficient Value	Variable	Coefficient Value
Hemoglobin <10 g/dL	1.50	Age > 65 years	3.19
Hemoglobin 10-12 g/dL	0.85	Age 45-65 years	1.65
D-Dimer > 1,000 ng/mL	0.76	CRP > 100 mg/L	1.21
CRP > 100 mg/L	0.64	Platelets < 100 per $\mu$ L	1.20
WBC > 11,000 cells/mm <sup>3</sup>	0.59	WBC > 11,000 cells/mm <sup>3</sup>	0.87
Male Sex	0.54	D-Dimer > 2,000 ng/mL	0.58
Internal Validation			
Statistic	Estimate (95% CI)	Statistic	Estimate (95% CI)
Harrell's Survival C-Statistic (Concordance)	0.785 (0.769, 0.800)	Harrell's Survival C-Statistic (Concordance)	0.857 (0.841, 0.874)
AKI in 3 Days AUC	0.787 (0.759, 0.814)	Death in 30 Days AUC	0.872 (0.854, 0.890)

AKI = acute kidney injury, CRP = C-reactive protein, WBC = white blood cells, AUC = area under the curve, CI = confidence interval

**Table S2.** Coefficients from fully adjusted Cox regression models and internal validation statistics using these coefficient linear predictions.

AKI		Death	
Fully Adjusted Model Coefficients			
Variable	Coefficient Value	Variable	Coefficient Value
Age 45-65 years	0.54	Age 45-65 years	1.67
Age > 65 years	0.77	Age > 65 years	3.15
Male Sex	0.41	Male Sex	0.14
Race Black	-0.12	Race Black	-0.41
Race Hispanic	-0.12	Race Hispanic	-0.47
Race Asian	-0.04	Race Asian	-0.79
Race Other	0.11	Race Other	-0.33
Medical Conditions 1	0.25	Medical Conditions 1	0.07
Medical Conditions 2	0.51	Medical Conditions 2	0.34
Medical Conditions 3+	0.60	Medical Conditions 3+	0.48
BMI 25-30 kg/m <sup>2</sup>	0.08	BMI 25-30 kg/m <sup>2</sup>	-0.25
BMI >30 kg/m <sup>2</sup>	0.35	BMI >30 kg/m <sup>2</sup>	-0.06
Temp < 97 F	0.06	Temp < 97 F	0.16
Temp > 100.4 F	0.46	Temp > 100.4 F	0.43
Heart rate < 60 beats/min	0.22	Heart rate < 60 beats/min	-0.03
Heart rate < 110 beats/min	0.11	Heart rate < 110 beats/min	0.58
SBP < 90 mmHg	0.64	SBP < 90 mmHg	0.74
SBP > 180 mmHg	-0.04	SBP > 180 mmHg	-0.11
WBC < 3,500 cells/mm <sup>3</sup>	-0.25	WBC < 3,500 cells/mm <sup>3</sup>	0.09
WBC > 11,000 cells/mm <sup>3</sup>	0.57	WBC > 11,000 cells/mm <sup>3</sup>	0.84
Hemoglobin <10 g/dL	0.77	Hemoglobin <10 g/dL	-0.13
Hemoglobin 10-12 g/dL	1.31	Hemoglobin 10-12 g/dL	0.03
Platelets < 100 per $\mu$ L	0.56	Platelets < 100 per $\mu$ L	0.96
CRP 50-100 mg/L	-0.04	CRP 50-100 mg/L	0.38
CRP > 100 mg/L	0.45	CRP > 100 mg/L	1.28
Ferritin 250-1000 $\mu$ g/L	0.26	Ferritin 250-1000 $\mu$ g/L	-0.10
Ferritin >1000 $\mu$ g/L	0.52	Ferritin >1000 $\mu$ g/L	0.13
D-Dimer 1,000-2,000 ng/mL	0.51	D-Dimer 1,000-2,000 ng/mL	0.19
D-Dimer > 2,000 ng/mL	0.75	D-Dimer > 2,000 ng/mL	0.60
Internal Validation			

<b>Statistic</b>	<b>Estimate (95% CI)</b>	<b>Statistic</b>	<b>Estimate (95% CI)</b>
Harrell's Survival C-Statistic (Concordance)	0.813 (0.798, 0.827)	Harrell's Survival C-Statistic (Concordance)	0.878 (0.863, 0.892)
AKI in 3 Days AUC	0.820 (0.794, 0.845)	Death in 30 Days AUC	0.893 (0.878, 0.909)

For peer review only

**Table S3.** Sensitivity, specificity, and likelihood ratios (LR) for positive and negative results of risk scores predicting acute kidney injury (AKI) within 3 days and death within 30 days of a positive COVID-19 test.

Cutoff	Sensitivity	Specificity	Positive LR	Negative LR
<b>Simplified AKI Risk Score (max 6)</b>				
<b>Rule in</b>				
0	1.000	0.000	1.000	NA
1	0.992	0.154	1.170	0.050
2	0.892	0.455	1.640	0.240
3	0.759	0.713	2.640	0.340
4	0.526	0.860	3.750	0.550
5	0.257	0.946	4.770	0.790
6	0.068	0.989	6.400	0.940
7	0.000	1.000	NA	1.000
<b>Simplified Death Risk Score (max 7)</b>				
0	1.000	0.000	1.000	NA
1	1.000	0.156	1.190	0.000
2	0.994	0.233	1.300	0.030
3	0.984	0.433	1.740	0.040
4	0.891	0.665	2.660	0.160
5	0.637	0.890	5.760	0.410
6	0.224	0.978	10.400	0.790
7	0.019	1.000	Inf	0.980
8	0.000	1.000	NA	1.000

Cutoff denotes treating a score greater than or equal a cutoff value as a positive.

Positive likelihood ratio (LR) is sensitivity / (1-specificity)

Negative likelihood ratio (LR) is (1-sensitivity) / specificity

Sensitivity 1 specificity 0 indicates all individuals identified as positive

Sensitivity 0 specificity 1 indicates all individuals identified as negative

Approximate probability changes can be obtained by  $\approx 0.18 * \ln(\text{LR})$  (McGee 2002)

**Table S4.** Multivariable AKI cause-specific hazard (AKI event, death censor) and AKI subdistribution hazard (AKI and death competing risks) model results.

Variable	Cause-Specific	Subdistribution
Age (years)		
<45	Reference	Reference
45-65	<b>1.71 (1.33, 2.21)</b>	<b>1.67 (1.31, 2.14)</b>
>65	<b>2.16 (1.66, 2.80)</b>	<b>1.92 (1.48, 2.50)</b>
Sex (Male)	<b>1.51 (1.28, 1.77)</b>	<b>1.53 (1.29, 1.81)</b>
Race		
White	Reference	Reference
Black	0.89 (0.72, 1.11)	0.91 (0.73, 1.14)
Hispanic	0.89 (0.58, 1.38)	0.96 (0.65, 1.41)
Asian	0.96 (0.65, 1.43)	0.97 (0.67, 1.41)
Other	1.11 (0.90, 1.37)	1.13 (0.91, 1.40)
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.28 (1.07, 1.53)</b>	<b>1.27 (1.06, 1.53)</b>
2	<b>1.67 (1.30, 2.13)</b>	<b>1.66 (1.29, 2.12)</b>
3+	<b>1.82 (1.21, 2.75)</b>	<b>1.81 (1.18, 2.77)</b>
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.09 (0.89, 1.33)	1.11 (0.90, 1.38)
>30	<b>1.42 (1.17, 1.74)</b>	<b>1.47 (1.19, 1.81)</b>
Temperature (F)		
97-100.4	Reference	Reference
<97	1.07 (0.75, 1.51)	1.03 (0.71, 1.48)
>100.4	<b>1.59 (1.34, 1.88)</b>	<b>1.62 (1.37, 1.91)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.24 (0.95, 1.63)	1.30 (0.98, 1.72)
>110	1.11 (0.85, 1.47)	1.04 (0.78, 1.38)
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.90 (1.41, 2.57)</b>	<b>1.73 (1.28, 2.35)</b>
>180	0.96 (0.55, 1.67)	1.00 (0.55, 1.84)
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.78 (0.55, 1.09)	0.79 (0.56, 1.12)
>11	<b>1.77 (1.49, 2.12)</b>	<b>1.68 (1.39, 2.04)</b>
Hemoglobin (g/dL)		
>12	Reference	Reference
10-12	<b>2.15 (1.75, 2.64)</b>	<b>2.27 (1.83, 2.81)</b>

<10	<b>3.72 (3.03, 4.57)</b>	<b>3.94 (3.17, 4.90)</b>
Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.74 (1.30, 2.34)</b>	<b>1.63 (1.19, 2.24)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.96 (0.77, 1.20)	0.94 (0.76, 1.18)
>100	<b>1.57 (1.29, 1.91)</b>	<b>1.48 (1.20, 1.82)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	<b>1.29 (1.03, 1.63)</b>	<b>1.33 (1.05, 1.69)</b>
>1000	<b>1.69 (1.31, 2.17)</b>	<b>1.70 (1.31, 2.21)</b>
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.67 (1.33, 2.09)</b>	<b>1.70 (1.36, 2.13)</b>
>2000	<b>2.11 (1.68, 2.65)</b>	<b>2.07 (1.63, 2.63)</b>

**Table S5.** Multiple Imputation Multivariable Cox Regression Results.

Variable	AKI	Death
Age (years)		
<45	Reference	Reference
45-65	<b>1.58 (1.22, 2.04)</b>	<b>4.60 (2.07, 10.3)</b>
>65	<b>1.86 (1.43, 2.43)</b>	<b>18.3 (8.47, 39.6)</b>
Sex (Male)	<b>1.42 (1.20, 1.68)</b>	1.05 (0.83, 1.33)
Race		
White	Reference	Reference
Black	0.87 (0.69, 1.08)	<b>0.65 (0.47, 0.89)</b>
Hispanic	0.97 (0.63, 1.50)	0.66 (0.33, 1.32)
Asian	0.92 (0.61, 1.38)	<b>0.39 (0.19, 0.80)</b>
Other	1.05 (0.85, 1.30)	<b>0.67 (0.47, 0.96)</b>
Medical Conditions (number)		
0	Reference	Reference
1	<b>1.32 (1.10, 1.58)</b>	1.07 (0.82, 1.39)
2	<b>1.62 (1.25, 2.09)</b>	1.33 (0.94, 1.89)
3+	<b>1.88 (1.24, 2.87)</b>	1.62 (0.94, 2.79)
Body Mass Index (kg/m <sup>2</sup> )		
<25	Reference	Reference
25-30	1.10 (0.90, 1.36)	0.81 (0.61, 1.07)
>30	<b>1.33 (1.09, 1.63)</b>	0.86 (0.65, 1.13)
Temperature (F)		
97-100.4	Reference	Reference
<97	0.95 (0.66, 1.36)	1.11 (0.69, 1.77)
>100.4	<b>1.40 (1.18, 1.66)</b>	<b>1.40 (1.09, 1.81)</b>
Heart Rate (beats/min)		
60-110	Reference	Reference
<60	1.13 (0.86, 1.48)	0.86 (0.58, 1.30)
>110	0.98 (0.74, 1.31)	1.41 (0.95, 2.08)
Systolic Blood Pressure (mmHg)		
90-180	Reference	Reference
<90	<b>1.74 (1.28, 2.37)</b>	<b>1.76 (1.19, 2.60)</b>
>180	1.22 (0.68, 2.19)	1.16 (0.52, 2.55)
Respiratory Rate (per minute)		
<20	Reference	Reference
>20	<b>1.72 (1.45, 2.03)</b>	<b>1.98 (1.53, 2.55)</b>
White Blood Cell (thousand cells/mm <sup>3</sup> )		
3.5-11	Reference	Reference
<3.5	0.81 (0.58, 1.15)	1.25 (0.81, 1.95)
>11	<b>1.61 (1.34, 1.93)</b>	<b>1.95 (1.52, 2.51)</b>
Hemoglobin (g/dL)		

>12	Reference	Reference
10-12	<b>2.02 (1.64, 2.49)</b>	0.81 (0.60, 1.09)
<10	<b>3.31 (2.68, 4.08)</b>	0.86 (0.65, 1.14)
Platelets (per $\mu\text{L}$ )		
>100	Reference	Reference
<100	<b>1.85 (1.37, 2.49)</b>	<b>2.51 (1.72, 3.68)</b>
C-Reactive Protein (mg/L)		
<50	Reference	Reference
50-100	0.99 (0.79, 1.24)	<b>1.60 (1.10, 2.33)</b>
>100	<b>1.47 (1.20, 1.80)</b>	<b>3.18 (2.32, 4.37)</b>
Ferritin ( $\mu\text{g/L}$ )		
<250	Reference	Reference
250-1000	1.18 (0.93, 1.50)	0.77 (0.54, 1.12)
>1000	<b>1.48 (1.14, 1.91)</b>	0.89 (0.60, 1.32)
D-Dimer (ng/mL)		
<1000	Reference	Reference
1000-2000	<b>1.59 (1.27, 2.00)</b>	1.16 (0.82, 1.63)
>2000	<b>2.03 (1.60, 2.57)</b>	<b>1.73 (1.23, 2.44)</b>
Interleukin-6 (IU/mL)		
<40	Reference	Reference
40-80	<b>1.39 (1.03, 1.86)</b>	<b>2.75 (1.80, 4.21)</b>
>80	<b>1.91 (1.50, 2.43)</b>	<b>3.07 (2.01, 4.69)</b>

Pooled hazard ratios calculated using 10 different imputation datasets with imputed values for missing respiratory rate and IL-6.



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7-8 7-8 7-8 7-8 7-8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
10				
11	<b>Discussion</b>			
12				
13	Key results	18	Summarise key results with reference to study objectives	12-14
14				
15	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
18				
19				
20	Generalisability	21	Discuss the generalisability (external validity) of the study results	15
21				
22	<b>Other information</b>			
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16
24				
25				

26 \*Give information separately for exposed and unexposed groups.

27  
28  
29 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60